|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions increases expression decreases expression |
ISO |
[Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; ABCB1 protein affects the susceptibility to [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil]; ABCB1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein] Cyclophosphamide results in decreased expression of ABCB1 mRNA; Cyclophosphamide results in decreased expression of ABCB1A mRNA |
CTD |
PMID:12576456 PMID:20041327 PMID:20623750 PMID:30563925 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
multiple interactions decreases response to substance |
ISO |
ABCC1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] ABCC1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:11778547 PMID:12576456 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
ABCG2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] |
CTD |
PMID:12576456 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Abhd3 |
abhydrolase domain containing 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ABHD3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr18:10,644,411...10,706,784
Ensembl chr18:10,642,092...10,706,771
|
|
G |
Abi2 |
abl interactor 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ABI2 mRNA |
CTD |
PMID:27466211 |
|
NCBI chr 1:60,444,927...60,521,104
Ensembl chr 1:60,448,778...60,520,317
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ACE mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions increases expression |
ISO |
Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of ACHE protein] |
CTD |
PMID:37419146 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ACKR3 mRNA |
CTD |
PMID:20032115 |
|
NCBI chr 1:90,131,702...90,143,446
Ensembl chr 1:90,131,702...90,144,473
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ACOD1 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr14:103,284,448...103,294,009
Ensembl chr14:103,284,413...103,294,009
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
multiple interactions increases expression |
EXP |
Dexrazoxane inhibits the reaction [Cyclophosphamide results in increased expression of ACSL4 protein] |
CTD |
PMID:37690746 |
|
NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531
|
|
G |
Actb |
actin, beta |
decreases expression affects expression |
ISO |
Cyclophosphamide results in decreased expression of ACTB mRNA Cyclophosphamide affects the expression of ACTB mRNA |
CTD |
PMID:10859244 PMID:12167460 |
|
NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
|
|
G |
Adam24 |
ADAM metallopeptidase domain 24 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ADAM24 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:41,128,118...41,135,238
Ensembl chr 8:41,128,118...41,135,238
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif 9 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ADAMTS9 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 6:92,749,680...92,921,431
Ensembl chr 6:92,749,680...92,920,473
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
affects expression increases expression |
ISO |
Cyclophosphamide affects the expression of ADCYAP1 mRNA Cyclophosphamide results in increased expression of ADCYAP1 protein |
CTD |
PMID:9776515 PMID:10754506 PMID:18563302 |
|
NCBI chr17:93,506,448...93,513,967
Ensembl chr17:93,506,445...93,513,965
|
|
G |
Adcyap1r1 |
adenylate cyclase activating polypeptide 1 receptor 1 |
affects expression |
ISO |
Cyclophosphamide affects the expression of ADCYAP1R1 mRNA |
CTD |
PMID:18563302 |
|
NCBI chr 6:55,428,486...55,478,440
Ensembl chr 6:55,428,963...55,478,436
|
|
G |
Adm |
adrenomedullin |
affects response to substance |
ISO |
ADM protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027
|
|
G |
Afp |
alpha fetoprotein |
affects expression |
EXP |
Cyclophosphamide affects the expression of AFP protein |
CTD |
PMID:6177358 |
|
NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766
|
|
G |
Agl |
amylo-1,6-glucosidase, 4-alpha-glucanotransferase |
affects response to substance |
ISO |
AGL protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 3:116,533,648...116,601,815
Ensembl chr 3:116,533,648...116,601,815
|
|
G |
Akap8 |
A kinase anchor protein 8 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of AKAP8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:32,522,646...32,540,212
Ensembl chr17:32,522,646...32,540,212
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions decreases expression |
ISO |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of AKT1 protein] |
CTD |
PMID:19996110 PMID:25446862 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alad |
aminolevulinate, delta-, dehydratase |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein |
CTD |
PMID:19162187 |
|
NCBI chr 4:62,422,762...62,438,300
Ensembl chr 4:62,427,406...62,438,155
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ALCAM mRNA |
CTD |
PMID:21041162 |
|
NCBI chr16:52,069,359...52,273,444
Ensembl chr16:52,069,359...52,274,437
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
affects response to substance decreases response to substance increases expression |
ISO |
ALDH1A1 protein affects the susceptibility to Cyclophosphamide ALDH1A1 protein results in decreased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:12513786 PMID:17403535 PMID:18854779 |
|
NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2, mitochondrial |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ALDH2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase family 3, subfamily A1 |
affects response to substance |
ISO |
ALDH3A1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:18854779 |
|
NCBI chr11:61,099,336...61,109,244
Ensembl chr11:61,098,363...61,109,247
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ALOX5AP mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 5:149,201,814...149,224,963
Ensembl chr 5:149,201,577...149,224,963
|
|
G |
Alyref |
Aly/REF export factor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ALYREF mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:120,485,330...120,489,342
Ensembl chr11:120,482,947...120,489,191
|
|
G |
Amfr |
autocrine motility factor receptor |
multiple interactions |
ISO |
AMFR mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 8:94,698,216...94,739,301
Ensembl chr 8:94,698,216...94,739,470
|
|
G |
Amh |
anti-Mullerian hormone |
multiple interactions decreases expression |
ISO |
Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of AMH protein] |
CTD |
PMID:32456565 |
|
NCBI chr10:80,641,074...80,643,513
Ensembl chr10:80,641,077...80,643,482
|
|
G |
Angpt1 |
angiopoietin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ANGPT1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr15:42,288,063...42,540,373
Ensembl chr15:42,288,119...42,540,373
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of APAF1 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632
|
|
G |
Apex1 |
apurinic/apyrimidinic endonuclease 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of APEX1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr14:51,162,406...51,164,645
Ensembl chr14:51,162,425...51,164,596
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of APOB mRNA |
CTD |
PMID:18246545 |
|
NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835
|
|
G |
Apoe |
apolipoprotein E |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of APOE mRNA Cyclophosphamide results in increased expression of APOE mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
Arg1 |
arginase, liver |
increases expression affects expression decreases expression |
EXP ISO |
Cyclophosphamide results in increased expression of ARG1 mRNA Cyclophosphamide affects the expression of ARG1 mRNA Cyclophosphamide results in decreased expression of ARG1 mRNA |
CTD |
PMID:18246545 PMID:21068404 |
|
NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382
|
|
G |
Arhgdib |
Rho, GDP dissociation inhibitor beta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ARHGDIB mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 6:136,900,653...136,918,895
Ensembl chr 6:136,900,653...136,918,897
|
|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ARHGEF26 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 3:62,244,946...62,369,642
Ensembl chr 3:62,245,765...62,369,642
|
|
G |
Asns |
asparagine synthetase |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ASNS mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:7,675,169...7,693,209
Ensembl chr 6:7,675,169...7,693,254
|
|
G |
Atf2 |
activating transcription factor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ATF2 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 2:73,646,853...73,723,094
Ensembl chr 2:73,646,853...73,722,983
|
|
G |
Atf5 |
activating transcription factor 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ATF5 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:44,461,680...44,466,082
Ensembl chr 7:44,461,680...44,466,082
|
|
G |
Atg3 |
autophagy related 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ATG3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr16:44,979,192...45,008,901
Ensembl chr16:44,979,148...45,008,901
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions decreases expression |
EXP |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein] |
CTD |
PMID:32151603 |
|
NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions decreases expression |
EXP |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein] |
CTD |
PMID:32151603 |
|
NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575
|
|
G |
Aurkb |
aurora kinase B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of AURKB mRNA |
CTD |
PMID:11599041 |
|
NCBI chr11:68,936,477...68,942,490
Ensembl chr11:68,936,473...68,942,490
|
|
G |
Axl |
AXL receptor tyrosine kinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of AXL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:25,455,925...25,488,502
Ensembl chr 7:25,456,698...25,488,130
|
|
G |
B3galnt2 |
UDP-GalNAc:betaGlcNAc beta 1,3-galactosaminyltransferase, polypeptide 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of B3GALNT2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:14,129,059...14,173,688
Ensembl chr13:14,129,054...14,173,688
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of BAD mRNA Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAD protein] |
CTD |
PMID:11599041 PMID:29753871 |
|
NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267
|
|
G |
Bag1 |
BCL2-associated athanogene 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BAG1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 4:40,936,398...40,948,294
Ensembl chr 4:40,936,398...40,948,294
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of BAX mRNA; Cyclophosphamide results in increased expression of BAX protein Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein] |
CTD |
PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbc3 |
BCL2 binding component 3 |
multiple interactions increases expression |
ISO |
sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA] |
CTD |
PMID:32197949 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Bbs4 |
Bardet-Biedl syndrome 4 |
multiple interactions |
ISO |
BBS4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:59,229,249...59,260,791
Ensembl chr 9:59,229,273...59,260,791
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases activity |
ISO |
[Melphalan co-treated with Thiotepa co-treated with Cyclophosphamide] results in decreased expression of BCHE protein Cyclophosphamide results in decreased activity of BCHE protein |
CTD |
PMID:4672170 PMID:4959505 |
|
NCBI chr 3:73,543,138...73,615,767
Ensembl chr 3:73,543,141...73,615,748
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of BCL2 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of BCL2 protein; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of BCL2 mRNA; [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein] Cyclophosphamide results in increased expression of BCL2 mRNA Cyclophosphamide results in decreased expression of BCL2 mRNA; Cyclophosphamide results in decreased expression of BCL2 protein Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] |
CTD |
PMID:11723234 PMID:14503796 PMID:15582267 PMID:16322899 PMID:21182165 PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 PMID:33737021 More...
|
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
increases expression decreases expression |
ISO EXP |
Cyclophosphamide results in increased expression of BCL2L1 mRNA Cyclophosphamide results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:11599041 PMID:33737021 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions increases expression |
ISO |
sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA] |
CTD |
PMID:32197949 |
|
NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
|
|
G |
Bcl2l2 |
BCL2-like 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BCL2L2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr14:55,120,900...55,125,691
Ensembl chr14:55,120,834...55,125,691
|
|
G |
Bcl6 |
B cell leukemia/lymphoma 6 |
decreases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of BCL6 mRNA Cyclophosphamide metabolite results in decreased expression of BCL6 mRNA |
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr16:23,780,058...23,807,602
Ensembl chr16:23,783,802...23,807,602
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase, type 1 |
affects response to substance |
ISO |
BDH1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr16:31,241,115...31,277,719
Ensembl chr16:31,241,098...31,277,719
|
|
G |
Bdkrb1 |
bradykinin receptor, beta 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BDKRB1 mRNA |
CTD |
PMID:10498854 PMID:15576455 |
|
NCBI chr12:105,570,350...105,571,770
Ensembl chr12:105,569,344...105,571,687
|
|
G |
Bdkrb2 |
bradykinin receptor, beta 2 |
affects expression |
ISO |
Cyclophosphamide affects the expression of BDKRB2 mRNA |
CTD |
PMID:15576455 |
|
NCBI chr12:105,529,431...105,561,503
Ensembl chr12:105,529,485...105,561,496
|
|
G |
Bdnf |
brain derived neurotrophic factor |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of BDNF mRNA; Cyclophosphamide results in increased expression of BDNF protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of BDNF protein] |
CTD |
PMID:10683293 PMID:32615180 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Becn1 |
beclin 1, autophagy related |
multiple interactions decreases expression |
ISO EXP |
BECN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] Cyclophosphamide results in decreased expression of BECN1 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein] |
CTD |
PMID:16896004 PMID:32151603 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Bik |
BCL2-interacting killer |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BIK mRNA |
CTD |
PMID:17403535 |
|
NCBI chr15:83,410,992...83,428,836
Ensembl chr15:83,411,063...83,428,835
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of BIRC3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 9:7,848,698...7,873,199
Ensembl chr 9:7,848,700...7,873,187
|
|
G |
Blvrb |
biliverdin reductase B |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BLVRB protein |
CTD |
PMID:9006340 |
|
NCBI chr 7:27,147,403...27,165,406
Ensembl chr 7:27,147,403...27,165,569
|
|
G |
Bpi |
bactericidal permeablility increasing protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BPI mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 2:158,099,983...158,126,453
Ensembl chr 2:158,100,014...158,126,451
|
|
G |
Brpf1 |
bromodomain and PHD finger containing, 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BRPF1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 6:113,283,824...113,301,823
Ensembl chr 6:113,284,098...113,301,821
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr19:8,814,831...8,826,047
Ensembl chr19:8,814,831...8,826,047
|
|
G |
Bsg |
basigin |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of BSG mRNA |
CTD |
PMID:15331540 |
|
NCBI chr10:79,540,192...79,547,813
Ensembl chr10:79,540,325...79,547,803
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of BTG1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:96,452,863...96,458,675
Ensembl chr10:96,452,868...96,458,671
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BTG2 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr 1:134,002,603...134,006,893
Ensembl chr 1:134,002,908...134,006,858
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
multiple interactions |
ISO |
BTG3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr16:78,156,748...78,174,069
Ensembl chr16:78,129,525...78,174,080
|
|
G |
Bub3 |
BUB3 mitotic checkpoint protein |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BUB3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 7:131,162,081...131,173,625
Ensembl chr 7:131,161,951...131,173,624
|
|
G |
C1qa |
complement component 1, q subcomponent, alpha polypeptide |
increases expression |
EXP |
Cyclophosphamide results in increased expression of C1QA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114
|
|
G |
C3 |
complement component 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of C3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136
|
|
G |
Cabp1 |
calcium binding protein 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CABP1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 5:115,306,750...115,332,440
Ensembl chr 5:115,306,748...115,332,440
|
|
G |
Cabp2 |
calcium binding protein 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CABP2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr19:4,131,469...4,137,340
Ensembl chr19:4,131,578...4,137,340
|
|
G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of CACNA1H protein 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein |
CTD |
PMID:29129814 |
|
NCBI chr17:25,593,259...25,655,308
Ensembl chr17:25,593,259...25,652,759
|
|
G |
Calca |
calcitonin/calcitonin-related polypeptide, alpha |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of CALCA protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of CALCA protein] |
CTD |
PMID:32615180 |
|
NCBI chr 7:114,225,223...114,236,145
Ensembl chr 7:114,230,713...114,235,592
|
|
G |
Calr |
calreticulin |
increases expression decreases expression |
ISO |
Cyclophosphamide results in increased expression of CALR mRNA Cyclophosphamide results in decreased expression of CALR mRNA |
CTD |
PMID:11599041 PMID:11906922 PMID:18246545 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Canx |
calnexin |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CANX mRNA |
CTD |
PMID:11906922 |
|
NCBI chr11:50,184,784...50,216,500
Ensembl chr11:50,184,788...50,216,500
|
|
G |
Capn2 |
calpain 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CAPN2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:182,294,818...182,345,175
Ensembl chr 1:182,294,825...182,345,173
|
|
G |
Car12 |
carbonic anhydrase 12 |
multiple interactions |
ISO |
CA12 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:66,619,026...66,674,127
Ensembl chr 9:66,620,968...66,674,127
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases expression increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of CA2 mRNA Cyclophosphamide results in increased expression of CAR2 mRNA |
CTD |
PMID:15331540 PMID:17403535 |
|
NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830
|
|
G |
Car7 |
carbonic anhydrase 7 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CAR7 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:105,261,326...105,276,979
Ensembl chr 8:105,261,321...105,276,975
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CARS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 7:143,110,967...143,153,827
Ensembl chr 7:143,110,967...143,153,827
|
|
G |
Casp1 |
caspase 1 |
decreases expression increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in decreased expression of CASP1 mRNA Cyclophosphamide results in increased expression of CASP1 mRNA Cyclophosphamide results in increased expression of CASP1 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein] |
CTD |
PMID:17403535 PMID:21041162 PMID:35762198 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases response to substance increases expression increases activity increases cleavage |
ISO EXP |
[Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP3 protein CASP3 protein alternative form results in decreased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of CASP3 mRNA ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein] Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; Cyclophosphamide results in increased expression of and results in increased activity of CASP3 protein; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of and results in increased activity of CASP3 protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein] |
CTD |
PMID:11723234 PMID:14503796 PMID:16675587 PMID:17020986 PMID:17898787 PMID:30506662 PMID:32197949 PMID:32456565 PMID:35762198 PMID:37419146 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp4 |
caspase 4, apoptosis-related cysteine peptidase |
increases cleavage multiple interactions |
ISO |
Cyclophosphamide results in increased cleavage of CASP4 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein] |
CTD |
PMID:32197949 |
|
NCBI chr 9:5,308,816...5,336,791
Ensembl chr 9:5,308,828...5,336,783
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases response to substance |
ISO |
[Methotrexate results in increased expression of CASP8 protein] which results in increased susceptibility to Cyclophosphamide metabolite; Cyclophosphamide metabolite results in increased expression of and results in increased cleavage of CASP8 protein; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP8 protein CASP8 protein results in increased susceptibility to Cyclophosphamide metabolite |
CTD |
PMID:17898787 PMID:22010212 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity increases expression |
ISO EXP |
BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP9 protein Cyclophosphamide results in increased expression of CASP9 protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP9 protein] |
CTD |
PMID:11723234 PMID:17898787 PMID:30506662 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
decreases expression multiple interactions affects activity decreases activity |
ISO EXP |
Cyclophosphamide results in decreased expression of CAT protein mangiferin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; pimagedine inhibits the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Quercetin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein] Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; cinnamic acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Eicosapentaenoic Acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CAT mRNA] Cyclophosphamide results in decreased expression of CAT mRNA; Cyclophosphamide results in decreased expression of CAT protein |
CTD |
PMID:16076520 PMID:19107871 PMID:20052769 PMID:20957680 PMID:21772021 PMID:22285266 PMID:23542512 PMID:23695977 PMID:25753322 PMID:27633142 PMID:29753871 PMID:33992719 PMID:34748891 PMID:35906875 More...
|
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccin |
calicin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCIN protein |
CTD |
PMID:17475930 |
|
NCBI chr 4:43,983,504...43,985,533
Ensembl chr 4:43,983,483...43,985,423
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression decreases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of CCL2 mRNA Cyclophosphamide results in decreased expression of CCL2 protein naringin inhibits the reaction [Cyclophosphamide results in increased expression of CCL2 mRNA] Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein] |
CTD |
PMID:18848347 PMID:21068404 PMID:33992719 PMID:36416909 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl25 |
C-C motif chemokine ligand 25 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCL25 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:4,375,207...4,410,020
Ensembl chr 8:4,375,210...4,410,020
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in decreased expression of CCL3 protein Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein] |
CTD |
PMID:21880982 PMID:36416909 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CCL7 mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351
|
|
G |
Ccl8 |
C-C motif chemokine ligand 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CCL8 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:82,006,011...82,007,625
Ensembl chr11:82,006,011...82,007,625
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CCL9 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:83,463,743...83,469,462
Ensembl chr11:83,463,745...83,469,462
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCNA2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCND1 protein |
CTD |
PMID:33737021 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd2 |
cyclin D2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CCND2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCND3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr17:47,815,976...47,910,614
Ensembl chr17:47,815,976...47,910,616
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CCR5 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCR8 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 9:119,921,199...119,923,972
Ensembl chr 9:119,921,180...119,923,972
|
|
G |
Ccr9 |
C-C motif chemokine receptor 9 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCR9 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:123,596,276...123,612,522
Ensembl chr 9:123,507,504...123,613,395
|
|
G |
Cct3 |
chaperonin containing TCP1 subunit 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCT3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 3:88,204,442...88,229,073
Ensembl chr 3:88,204,423...88,229,074
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCT5 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr15:31,590,946...31,601,992
Ensembl chr15:31,590,946...31,601,950
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCT7 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 6:85,428,487...85,445,459
Ensembl chr 6:85,428,496...85,445,457
|
|
G |
Cd14 |
CD14 antigen |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CD14 mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851
|
|
G |
Cd151 |
CD151 antigen |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CD151 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:141,047,275...141,051,394
Ensembl chr 7:141,047,305...141,051,386
|
|
G |
Cd2 |
CD2 antigen |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:101,183,224...101,195,255
Ensembl chr 3:101,183,215...101,195,255
|
|
G |
Cd27 |
CD27 antigen |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD27 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:125,209,583...125,214,014
Ensembl chr 6:125,209,585...125,213,973
|
|
G |
Cd28 |
CD28 antigen |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD28 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518
|
|
G |
Cd38 |
CD38 antigen |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CD38 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:44,026,153...44,069,714
Ensembl chr 5:44,025,895...44,069,717
|
|
G |
Cd3d |
CD3 antigen, delta polypeptide |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD3D mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:44,893,067...44,898,350
Ensembl chr 9:44,893,084...44,898,637
|
|
G |
Cd3e |
CD3 antigen, epsilon polypeptide |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD3E mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:44,910,033...44,920,961
Ensembl chr 9:44,910,038...44,920,925
|
|
G |
Cd3g |
CD3 antigen, gamma polypeptide |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD3G mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:44,880,870...44,891,729
Ensembl chr 9:44,880,870...44,891,729
|
|
G |
Cd4 |
CD4 antigen |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD4 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:124,841,656...124,865,210
Ensembl chr 6:124,841,655...124,865,184
|
|
G |
Cd40 |
CD40 antigen |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD40 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868
|
|
G |
Cd5 |
CD5 antigen |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD5 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr19:10,695,471...10,716,390
Ensembl chr19:10,694,480...10,716,366
|
|
G |
Cd6 |
CD6 antigen |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD6 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr19:10,766,703...10,807,427
Ensembl chr19:10,766,705...10,807,422
|
|
G |
Cd69 |
CD69 antigen |
decreases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of CD69 mRNA Cyclophosphamide metabolite results in decreased expression of CD69 mRNA |
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr 6:129,244,287...129,252,332
Ensembl chr 6:129,244,288...129,252,399
|
|
G |
Cd74 |
CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD74 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr18:60,936,921...60,945,724
Ensembl chr18:60,936,920...60,945,724
|
|
G |
Cd79b |
CD79B antigen |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD79B mRNA |
CTD |
PMID:15331540 |
|
NCBI chr11:106,202,167...106,205,388
Ensembl chr11:106,202,167...106,205,588
|
|
G |
Cd83 |
CD83 antigen |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD83 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr13:43,938,661...43,956,608
Ensembl chr13:43,938,251...43,956,608
|
|
G |
Cd84 |
CD84 antigen |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of CD84 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:171,667,261...171,718,288
Ensembl chr 1:171,667,265...171,718,285
|
|
G |
Cd8a |
CD8 subunit alpha |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD8A mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:71,350,411...71,356,155
Ensembl chr 6:71,350,411...71,356,157
|
|
G |
Cd8b1 |
CD8 subunit beta 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CD8B1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:71,299,772...71,314,476
Ensembl chr 6:71,299,772...71,314,478
|
|
G |
Cdc20 |
cell division cycle 20 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CDC20 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 4:118,290,098...118,294,540
Ensembl chr 4:118,290,098...118,294,549
|
|
G |
Cdh1 |
cadherin 1 |
affects expression |
ISO |
Cyclophosphamide affects the expression of CDH1 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdh2 |
cadherin 2 |
affects expression |
ISO |
Cyclophosphamide affects the expression of CDH2 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303
|
|
G |
Cdh3 |
cadherin 3 |
affects expression |
ISO |
Cyclophosphamide affects the expression of CDH3 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr 8:107,237,484...107,283,543
Ensembl chr 8:107,237,523...107,283,929
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CDK2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of CDKN1A mRNA |
CTD |
PMID:15331540 PMID:21527772 PMID:29445054 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CDKN1B mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn1c |
cyclin dependent kinase inhibitor 1C |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CDKN1C mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:143,012,076...143,014,735
Ensembl chr 7:143,012,076...143,014,787
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CDKN2D mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:21,199,759...21,202,553
Ensembl chr 9:21,199,706...21,202,703
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CEBPB mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CEL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:28,445,831...28,453,415
Ensembl chr 2:28,445,807...28,453,415
|
|
G |
Cfb |
complement factor B |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CFB mRNA |
CTD |
PMID:21041162 |
|
NCBI chr17:35,075,350...35,081,492
Ensembl chr17:35,075,350...35,081,494
|
|
G |
Cfi |
complement component factor i |
affects response to substance |
ISO |
CFI protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 3:129,630,432...129,668,978
Ensembl chr 3:129,629,533...129,668,981
|
|
G |
Chac1 |
ChaC, cation transport regulator 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CHAC1 mRNA; Cyclophosphamide results in decreased expression of CHAC1 mRNA |
CTD |
PMID:23824090 PMID:24356939 |
|
NCBI chr 2:119,181,723...119,184,807
Ensembl chr 2:119,181,710...119,184,862
|
|
G |
Champ1 |
chromosome alignment maintaining phosphoprotein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CHAMP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:13,919,699...13,931,637
Ensembl chr 8:13,919,641...13,931,639
|
|
G |
Chd5 |
chromodomain helicase DNA binding protein 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CHD5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:152,423,103...152,474,651
Ensembl chr 4:152,423,108...152,474,651
|
|
G |
Chga |
chromogranin A |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CHGA mRNA |
CTD |
PMID:15331540 |
|
NCBI chr12:102,521,200...102,531,286
Ensembl chr12:102,521,228...102,531,287
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CHRM5 protein |
CTD |
PMID:16125470 |
|
NCBI chr 2:112,306,055...112,365,487
Ensembl chr 2:112,309,516...112,311,114
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
affects expression decreases expression |
ISO |
Cyclophosphamide affects the expression of CITED2 mRNA Cyclophosphamide results in decreased expression of CITED2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr10:17,598,452...17,601,422
Ensembl chr10:17,598,966...17,601,422
|
|
G |
Ckm |
creatine kinase, muscle |
multiple interactions increases expression |
ISO |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein] |
CTD |
PMID:35762198 |
|
NCBI chr 7:19,145,019...19,155,508
Ensembl chr 7:19,138,701...19,156,766
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions decreases expression |
EXP |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein] |
CTD |
PMID:32151603 |
|
NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591
|
|
G |
Cldn4 |
claudin 4 |
multiple interactions decreases expression |
ISO |
Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein] |
CTD |
PMID:25451569 |
|
NCBI chr 5:134,973,977...134,975,788
Ensembl chr 5:134,973,973...134,975,788
|
|
G |
Clic4 |
chloride intracellular channel 4 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CLIC4 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 4:134,941,280...135,000,071
Ensembl chr 4:134,941,280...135,000,125
|
|
G |
Clip1 |
CAP-GLY domain containing linker protein 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CLIP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:123,715,857...123,822,527
Ensembl chr 5:123,715,858...123,822,681
|
|
G |
Coch |
cochlin |
affects response to substance |
ISO |
COCH protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr12:51,640,156...51,652,558
Ensembl chr12:51,640,124...51,652,554
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
EXP |
Cyclophosphamide results in increased expression of COMT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of COX7A2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 9:79,662,523...79,667,135
Ensembl chr 9:79,662,643...79,667,160
|
|
G |
Crabp2 |
cellular retinoic acid binding protein II |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CRABP2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:87,856,000...87,860,679
Ensembl chr 3:87,855,973...87,860,683
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CREB1 protein modified form |
CTD |
PMID:18299998 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of CREM mRNA; Cyclophosphamide results in decreased expression of CREM protein Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM mRNA]; Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM protein] |
CTD |
PMID:17624719 |
|
NCBI chr18:3,263,181...3,337,688
Ensembl chr18:3,266,048...3,337,748
|
|
G |
Crh |
corticotropin releasing hormone |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of CRH mRNA; Cyclophosphamide results in increased expression of CRH protein |
CTD |
PMID:15276878 PMID:16614059 PMID:17335920 |
|
NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CRHR2 protein |
CTD |
PMID:16614059 |
|
NCBI chr 6:55,067,033...55,110,001
Ensembl chr 6:55,067,034...55,110,001
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
multiple interactions increases secretion |
ISO |
allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of CRP protein] |
CTD |
PMID:31779506 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
multiple interactions |
EXP |
[Cyclophosphamide co-treated with Sizofiran] results in increased expression of CSF1 mRNA |
CTD |
PMID:10052129 |
|
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
affects activity increases expression |
ISO |
CSF2 protein affects the activity of Cyclophosphamide Cyclophosphamide results in increased expression of CSF2 protein |
CTD |
PMID:8349185 PMID:18848347 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Csk |
c-src tyrosine kinase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CSK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:57,533,929...57,560,758
Ensembl chr 9:57,533,929...57,560,914
|
|
G |
Cst7 |
cystatin F (leukocystatin) |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CST7 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 2:150,412,335...150,420,864
Ensembl chr 2:150,412,335...150,420,864
|
|
G |
Csta2 |
cystatin A family member 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CSTA mRNA |
CTD |
PMID:24356939 |
|
NCBI chr16:36,041,932...36,077,813
Ensembl chr16:36,041,838...36,077,810
|
|
G |
Cth |
cystathionine gamma lyase |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CTH protein |
CTD |
PMID:29129814 |
|
NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
|
|
G |
Ctnnbip1 |
catenin beta interacting protein 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CTNNBIP1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 4:149,602,698...149,650,894
Ensembl chr 4:149,602,693...149,650,894
|
|
G |
Ctnnd2 |
catenin delta 2 |
multiple interactions |
ISO |
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr15:30,172,680...31,029,490
Ensembl chr15:30,172,739...31,029,487
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases activity |
EXP ISO |
[Cyclophosphamide co-treated with Mecamylamine] results in increased expression of CTSD mRNA Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein] |
CTD |
PMID:18433785 PMID:25451569 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Ctsh |
cathepsin H |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CTSH mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 9:89,936,320...89,958,148
Ensembl chr 9:89,936,205...89,958,142
|
|
G |
Ctsl |
cathepsin L |
increases expression decreases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of CTSL mRNA Cyclophosphamide results in decreased expression of CTSL mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in decreased expression of CTSL mRNA] |
CTD |
PMID:17403535 PMID:30760223 |
|
NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CX3CL1 protein |
CTD |
PMID:16651033 |
|
NCBI chr 8:95,498,808...95,509,055
Ensembl chr 8:95,498,637...95,509,055
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CX3CR1 protein |
CTD |
PMID:16651033 |
|
NCBI chr 9:119,877,749...119,897,362
Ensembl chr 9:119,877,749...119,898,945
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CXCL1 protein |
CTD |
PMID:18848347 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
affects expression increases response to substance increases expression |
EXP |
Cyclophosphamide affects the expression of CXCL10 mRNA CXCL10 protein results in increased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of CXCL10 protein |
CTD |
PMID:18957084 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl11 |
chemokine (C-X-C motif) ligand 11 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CXCL11 protein |
CTD |
PMID:18957084 |
|
NCBI chr 5:92,507,403...92,511,155
Ensembl chr 5:92,507,403...92,513,344
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of CXCL12 mRNA Cyclophosphamide results in increased expression of CXCL12 mRNA Cyclophosphamide results in increased expression of CXCL12 mRNA; Cyclophosphamide results in increased expression of CXCL12 protein |
CTD |
PMID:12624490 PMID:16337237 PMID:19066630 PMID:20032115 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of CXCL8 mRNA Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL8 protein] Cyclophosphamide results in increased expression of CXCL5 mRNA |
CTD |
PMID:15331540 PMID:29594315 PMID:36416909 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Cyclophosphamide co-treated with Dexamethasone] inhibits the reaction [Paraquat results in increased expression of CXCL2 mRNA] |
CTD |
PMID:36031164 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression multiple interactions affects expression |
EXP |
Cyclophosphamide results in increased expression of CXCL1 mRNA; Cyclophosphamide results in increased expression of CXCL1 protein VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of CXCL1 protein] Cyclophosphamide affects the expression of CXCL3 mRNA |
CTD |
PMID:15331540 PMID:18483878 PMID:18957084 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
affects expression increases expression decreases expression |
EXP |
Cyclophosphamide affects the expression of CXCL9 mRNA Cyclophosphamide results in increased expression of CXCL9 mRNA; Cyclophosphamide results in increased expression of CXCL9 protein Cyclophosphamide results in decreased expression of CXCL9 protein |
CTD |
PMID:15331540 PMID:18957084 PMID:21041162 PMID:21880982 |
|
NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions affects localization decreases expression increases expression |
ISO EXP |
Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein] Cyclophosphamide affects the localization of CXCR4 protein Cyclophosphamide results in decreased expression of CXCR4 mRNA Cyclophosphamide results in increased expression of CXCR4 mRNA; Cyclophosphamide results in increased expression of CXCR4 protein |
CTD |
PMID:19066630 PMID:20032115 PMID:21041162 |
|
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Cxcr6 |
C-X-C motif chemokine receptor 6 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CXCR6 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:123,635,542...123,640,819
Ensembl chr 9:123,635,540...123,640,825
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
EXP |
Cyclophosphamide results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
EXP |
Cyclophosphamide results in decreased activity of CYP1A2 protein |
CTD |
PMID:18420780 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:12167460 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2a4 |
cytochrome P450, family 2, subfamily a, polypeptide 4 |
decreases activity |
EXP |
Cyclophosphamide results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr 7:26,006,617...26,014,513
Ensembl chr 7:26,006,594...26,014,513
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
multiple interactions affects hydroxylation increases hydroxylation increases response to substance increases expression increases metabolic processing increases activity |
ISO EXP |
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of CYP2B6 mRNA; Cyclophosphamide results in decreased expression of and results in decreased activity of CYP2B6 protein; CYP2B6 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide; CYP2B6 protein results in increased metabolism of and results in increased susceptibility to Cyclophosphamide; POR promotes the reaction [CYP2B6 results in increased susceptibility to Cyclophosphamide]; POR protein promotes the reaction [CYP2B6 protein results in increased susceptibility to Cyclophosphamide] CYP2B6 intron polymorphism affects the hydroxylation of Cyclophosphamide; CYP2B6 promoter polymorphism affects the hydroxylation of Cyclophosphamide CYP2B6 protein results in increased hydroxylation of Cyclophosphamide CYP2B6 protein results in increased susceptibility to Cyclophosphamide; CYP2B6 results in increased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of CYP2B10 mRNA CYP2B6 protein results in increased metabolism of Cyclophosphamide CYP2B6 protein results in increased activity of Cyclophosphamide |
CTD |
PMID:9766669 PMID:10919648 PMID:11389073 PMID:11723234 PMID:12498089 PMID:12872138 PMID:15248218 PMID:15769884 PMID:16183265 PMID:16322899 PMID:17041008 PMID:17502835 PMID:18212249 PMID:18633247 PMID:24819615 PMID:25860621 More...
|
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2b13 |
cytochrome P450, family 2, subfamily b, polypeptide 13 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CYP2B2 mRNA; Cyclophosphamide results in increased expression of CYP2B2 protein |
CTD |
PMID:16019949 PMID:17634551 |
|
NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
increases expression increases activity increases metabolic processing |
EXP ISO |
Cyclophosphamide results in increased expression of CYP2C29 mRNA CYP2C8 results in increased activity of Cyclophosphamide CYP2C6 results in increased metabolism of Cyclophosphamide |
CTD |
PMID:9241661 PMID:20566340 PMID:24819615 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Cyp2c38 |
cytochrome P450, family 2, subfamily c, polypeptide 38 |
decreases metabolic processing multiple interactions increases metabolic processing increases activity increases hydroxylation increases response to substance |
ISO |
CYP2C19 gene polymorphism results in decreased metabolism of Cyclophosphamide [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide; [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of Acrolein; CYP2C19 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide CYP2C19 protein results in increased metabolism of Cyclophosphamide CYP2C19 results in increased activity of Cyclophosphamide CYP2C19 protein results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:9241661 PMID:15248218 PMID:16116487 PMID:30500380 |
|
NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519
|
|
G |
Cyp2c52-ps |
cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene |
increases metabolic processing increases expression increases response to substance increases activity multiple interactions |
ISO |
CYP2C11 results in increased metabolism of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2C11 mRNA CYP2C18 results in increased susceptibility to Cyclophosphamide CYP2C18 results in increased activity of Cyclophosphamide POR promotes the reaction [CYP2C18 results in increased susceptibility to Cyclophosphamide] |
CTD |
PMID:9241661 PMID:9766669 PMID:16019949 PMID:20566340 |
|
NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
increases metabolic processing increases response to substance multiple interactions increases activity decreases activity |
ISO EXP |
CYP2C9 protein results in increased metabolism of Cyclophosphamide CYP2C9 protein results in increased susceptibility to Cyclophosphamide [GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased susceptibility to Cyclophosphamide] CYP2C9 results in increased activity of Cyclophosphamide Cyclophosphamide results in decreased activity of CYP2C9 protein |
CTD |
PMID:9241661 PMID:10991840 PMID:11377097 PMID:18420780 PMID:24819615 PMID:28744217 More...
|
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of Cyclophosphamide |
CTD |
PMID:11377097 |
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases metabolic processing |
ISO |
CYP2E1 results in increased metabolism of Cyclophosphamide |
CTD |
PMID:20566340 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
increases expression affects metabolic processing multiple interactions affects response to substance |
EXP ISO |
Cyclophosphamide results in increased expression of CYP3A13 mRNA CYP3A5 protein affects the metabolism of Cyclophosphamide CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] CYP3A5 gene polymorphism affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16087946 PMID:24819615 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Cyp3a44 |
cytochrome P450, family 3, subfamily a, polypeptide 44 |
decreases activity |
EXP |
Cyclophosphamide results in decreased activity of CYP3A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr 5:145,710,793...145,742,701
Ensembl chr 5:145,710,793...145,742,684
|
|
G |
Dcn |
decorin |
multiple interactions |
EXP |
DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]] |
CTD |
PMID:9509296 |
|
NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005
|
|
G |
Ddb1 |
damage specific DNA binding protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DDB1 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr19:10,582,961...10,607,186
Ensembl chr19:10,582,691...10,607,183
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
affects expression decreases expression increases expression multiple interactions |
ISO |
Cyclophosphamide affects the expression of DDIT3 mRNA Cyclophosphamide metabolite results in decreased expression of DDIT3 mRNA Cyclophosphamide results in increased expression of DDIT3 mRNA; Cyclophosphamide results in increased expression of DDIT3 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein] |
CTD |
PMID:18246545 PMID:24356939 PMID:32197949 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
affects response to substance |
ISO |
DDIT4 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr10:59,785,497...59,787,592
Ensembl chr10:59,785,491...59,787,656
|
|
G |
Deaf1 |
DEAF1, transcription factor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of DEAF1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:140,877,089...140,918,758
Ensembl chr 7:140,877,093...140,907,603
|
|
G |
Dlc1 |
deleted in liver cancer 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DLC1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:37,034,893...37,420,343
Ensembl chr 8:37,034,905...37,420,297
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
affects expression increases expression |
ISO |
Cyclophosphamide affects the expression of DNAJB1 mRNA Cyclophosphamide metabolite results in increased expression of DNAJB1 mRNA |
CTD |
PMID:18246545 PMID:24356939 |
|
NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of DNAJB4 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 3:151,887,217...151,915,720
Ensembl chr 3:151,884,148...151,915,939
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DNAJB6 protein |
CTD |
PMID:17475930 |
|
NCBI chr 5:29,940,896...29,991,476
Ensembl chr 5:29,940,686...30,023,132
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions decreases methylation increases expression |
ISO |
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein] Cyclophosphamide results in decreased methylation of DNMT1 protein Cyclophosphamide results in increased expression of DNMT1 protein |
CTD |
PMID:22007908 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dntt |
deoxynucleotidyltransferase, terminal |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of DNTT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr19:41,017,701...41,047,964
Ensembl chr19:41,017,714...41,047,964
|
|
G |
Dpf3 |
double PHD fingers 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of DPF3 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:83,260,525...83,534,510
Ensembl chr12:83,260,519...83,534,490
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DPYSL4 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:138,665,917...138,681,711
Ensembl chr 7:138,665,917...138,682,620
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding |
EXP |
Cyclophosphamide binds to DRD1 protein |
CTD |
PMID:11180191 |
|
NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding |
EXP |
Cyclophosphamide binds to DRD2 protein |
CTD |
PMID:11180191 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of DUSP10 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:183,766,575...183,807,833
Ensembl chr 1:183,745,499...183,807,833
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of DUSP2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:127,178,079...127,180,297
Ensembl chr 2:127,178,079...127,180,296
|
|
G |
Dzip1 |
DAZ interacting protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DZIP1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr14:119,112,927...119,162,947
Ensembl chr14:119,112,932...119,162,872
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
E2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr13:30,090,558...30,171,172
Ensembl chr13:30,090,558...30,170,046
|
|
G |
Ear6 |
eosinophil-associated, ribonuclease A family, member 6 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RNASE2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr14:52,091,225...52,092,100
Ensembl chr14:52,091,156...52,092,100
|
|
G |
Eda2r |
ectodysplasin A2 receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDA2R mRNA |
CTD |
PMID:21527772 |
|
NCBI chr X:96,375,936...96,420,786
Ensembl chr X:96,377,446...96,420,822
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDN1 protein |
CTD |
PMID:17562616 PMID:18548196 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDNRB mRNA |
CTD |
PMID:20849824 |
|
NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of EEF2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr10:81,012,465...81,018,343
Ensembl chr10:81,012,465...81,018,332
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
EGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil] |
CTD |
PMID:15981280 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egr1 |
early growth response 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of EGR1 mRNA Cyclophosphamide results in decreased expression of EGR1 mRNA Cyclophosphamide results in increased expression of EGR1 protein 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein |
CTD |
PMID:7498375 PMID:9776515 PMID:21041162 PMID:21527772 PMID:29129814 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of EGR2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:67,370,334...67,383,354
Ensembl chr10:67,371,305...67,378,018
|
|
G |
Egr4 |
early growth response 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of EGR4 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 6:85,488,103...85,490,571
Ensembl chr 6:85,488,103...85,490,571
|
|
G |
Eif1ax |
eukaryotic translation initiation factor 1A, X-linked |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF1AX mRNA |
CTD |
PMID:16322899 |
|
NCBI chr X:158,155,174...158,172,617
Ensembl chr X:158,155,174...158,172,924
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
ISO |
sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:32197949 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF4EBP1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702
|
|
G |
Elovl2 |
ELOVL fatty acid elongase 2 |
affects response to substance |
ISO |
ELOVL2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:41,335,858...41,373,879
Ensembl chr13:41,335,857...41,373,881
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EMP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 6:135,339,548...135,360,171
Ensembl chr 6:135,339,543...135,360,171
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EMP3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:45,567,447...45,570,850
Ensembl chr 7:45,567,447...45,570,828
|
|
G |
Epb41l2 |
erythrocyte membrane protein band 4.1 like 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of EPB41L2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr10:25,235,680...25,399,413
Ensembl chr10:25,235,696...25,399,417
|
|
G |
Ephx1 |
epoxide hydrolase 1, microsomal |
affects expression increases expression |
ISO |
Cyclophosphamide affects the expression of EPHX1 mRNA Cyclophosphamide results in increased expression of EPHX1 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469
|
|
G |
Epo |
erythropoietin |
multiple interactions decreases expression increases response to substance |
ISO |
angelicae sinensis extract inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA]; Astragali compound inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA] EPO protein results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:11245434 PMID:19627214 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ERAP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr13:74,787,692...74,841,321
Ensembl chr13:74,787,687...74,841,320
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] |
CTD |
PMID:9816327 PMID:15834928 PMID:15940066 PMID:16446318 PMID:16682728 PMID:17010609 More...
|
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
ERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 1:68,071,063...69,147,756
Ensembl chr 1:68,071,345...69,147,218
|
|
G |
Ercc1 |
excision repair cross-complementing rodent repair deficiency, complementation group 1 |
affects expression |
ISO |
Cyclophosphamide affects the expression of ERCC1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 7:19,079,016...19,090,449
Ensembl chr 7:19,078,703...19,090,449
|
|
G |
Ercc2 |
excision repair cross-complementing rodent repair deficiency, complementation group 2 |
affects expression multiple interactions increases expression |
ISO EXP |
Cyclophosphamide affects the expression of ERCC2 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of ERCC2 mRNA] |
CTD |
PMID:11906922 PMID:30760223 |
|
NCBI chr 7:19,115,942...19,129,619
Ensembl chr 7:19,115,935...19,129,619
|
|
G |
Erg |
ETS transcription factor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ERG mRNA |
CTD |
PMID:17403535 |
|
NCBI chr16:95,160,028...95,387,452
Ensembl chr16:95,160,028...95,387,452
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signalling 1 |
increases phosphorylation multiple interactions |
ISO |
Cyclophosphamide results in increased phosphorylation of ERN1 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:32197949 |
|
NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR2 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of ESRRA mRNA Cyclophosphamide results in increased expression of ESRRA mRNA |
CTD |
PMID:27281708 |
|
NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
|
|
G |
Evi2a |
ecotropic viral integration site 2a |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of EVI2A mRNA |
CTD |
PMID:24356939 |
|
NCBI chr11:79,417,386...79,421,435
Ensembl chr11:79,417,386...79,421,435
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of F2RL1 protein |
CTD |
PMID:15643279 |
|
NCBI chr13:95,648,226...95,661,748
Ensembl chr13:95,648,240...95,661,735
|
|
G |
F2rl2 |
coagulation factor II thrombin receptor like 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of F2RL2 protein |
CTD |
PMID:15643279 |
|
NCBI chr13:95,833,428...95,839,276
Ensembl chr13:95,833,361...95,839,247
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of F2RL3 protein |
CTD |
PMID:15643279 |
|
NCBI chr 8:73,488,287...73,490,526
Ensembl chr 8:73,488,508...73,490,502
|
|
G |
F3 |
coagulation factor III |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of F3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697
|
|
G |
Fam107b |
family with sequence similarity 107, member B |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of FAM107B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:3,705,049...3,783,179
Ensembl chr 2:3,571,525...3,783,179
|
|
G |
Fam234b |
family with sequence similarity 234, member B |
multiple interactions |
ISO |
FAM234B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 6:135,173,881...135,213,240
Ensembl chr 6:135,174,975...135,221,953
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression decreases expression |
ISO EXP |
[Cyclophosphamide co-treated with cacalol] results in decreased expression of FAS protein; [Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FAS Cyclophosphamide results in increased expression of FAS Cyclophosphamide results in increased expression of FAS mRNA; Cyclophosphamide results in increased expression of FAS protein Cyclophosphamide metabolite results in decreased expression of FAS mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of FAS mRNA] |
CTD |
PMID:10393266 PMID:16166447 PMID:20665104 PMID:24356939 PMID:25446862 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FASLG |
CTD |
PMID:16166447 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fau |
FAU ubiquitin like and ribosomal protein S30 fusion |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FAU mRNA |
CTD |
PMID:11599041 |
|
NCBI chr19:6,107,977...6,109,554
Ensembl chr19:6,107,874...6,109,554
|
|
G |
Fbxo40 |
F-box protein 40 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FBXO40 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr16:36,783,823...36,811,321
Ensembl chr16:36,783,822...36,810,829
|
|
G |
Fbxw7 |
F-box and WD-40 domain protein 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FBXW7 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr 3:84,721,901...84,886,505
Ensembl chr 3:84,722,575...84,886,505
|
|
G |
Fcer1g |
Fc receptor, IgE, high affinity I, gamma polypeptide |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FCER1G mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:171,057,141...171,061,918
Ensembl chr 1:171,057,141...171,061,934
|
|
G |
Fcgr3 |
Fc receptor, IgG, low affinity III |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FCGR3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:170,878,738...170,893,477
Ensembl chr 1:170,878,743...170,892,504
|
|
G |
Fcgrt |
Fc fragment of IgG receptor and transporter |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FCGRT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:44,742,417...44,753,246
Ensembl chr 7:44,742,414...44,753,275
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FHL1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr X:55,776,569...55,838,704
Ensembl chr X:55,777,147...55,838,706
|
|
G |
Fkbp1b |
FK506 binding protein 1b |
affects response to substance |
ISO |
FKBP1B protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr12:4,883,174...4,891,736
Ensembl chr12:4,883,174...4,891,591
|
|
G |
Fkbpl |
FK506 binding protein-like |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FKBPL mRNA |
CTD |
PMID:14503796 |
|
NCBI chr17:34,863,788...34,865,791
Ensembl chr17:34,863,738...34,865,298
|
|
G |
Flnc |
filamin C, gamma |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FLNC mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 6:29,433,150...29,461,888
Ensembl chr 6:29,433,255...29,461,882
|
|
G |
Flt3l |
FMS-like tyrosine kinase 3 ligand |
affects expression |
EXP |
Cyclophosphamide affects the expression of FLT3L mRNA |
CTD |
PMID:12624490 |
|
NCBI chr 7:44,780,607...44,785,914
Ensembl chr 7:44,779,212...44,785,856
|
|
G |
Fndc3b |
fibronectin type III domain containing 3B |
affects response to substance |
ISO |
FNDC3B protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 3:27,470,284...27,765,469
Ensembl chr 3:27,470,311...27,765,456
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions increases expression |
EXP ISO |
Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS mRNA] alfuzosin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein] |
CTD |
PMID:7498375 PMID:8801120 PMID:8808730 PMID:9776515 PMID:10749792 PMID:15099680 PMID:15217452 PMID:17240043 PMID:18093676 More...
|
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Foxp3 |
forkhead box P3 |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of FOXP3 mRNA; Cyclophosphamide results in decreased expression of FOXP3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein] |
CTD |
PMID:15591121 PMID:32151603 |
|
NCBI chr X:7,445,915...7,461,482
Ensembl chr X:7,439,883...7,461,484
|
|
G |
Foxp4 |
forkhead box P4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of FOXP4 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:48,178,058...48,235,401
Ensembl chr17:48,178,058...48,235,570
|
|
G |
Fpr2 |
formyl peptide receptor 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FPR2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr17:18,108,086...18,114,214
Ensembl chr17:18,108,086...18,114,214
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FSCN1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 5:142,946,110...142,958,944
Ensembl chr 5:142,946,098...142,958,940
|
|
G |
Fshb |
follicle stimulating hormone beta |
increases expression decreases secretion multiple interactions |
ISO |
Cyclophosphamide results in increased expression of FSHB protein Cyclophosphamide results in decreased secretion of FSHB protein Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of FSHB protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein] |
CTD |
PMID:6788612 PMID:25446862 PMID:32197949 PMID:32456565 |
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions decreases expression |
EXP |
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of FSHR mRNA] |
CTD |
PMID:31557371 |
|
NCBI chr17:89,292,380...89,508,103
Ensembl chr17:89,292,380...89,508,103
|
|
G |
Fyn |
Fyn proto-oncogene |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FYN mRNA |
CTD |
PMID:17403535 |
|
NCBI chr10:39,245,735...39,441,377
Ensembl chr10:39,244,851...39,441,377
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of G3BP1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:55,360,521...55,391,722
Ensembl chr11:55,360,511...55,395,664
|
|
G |
G6pc2 |
glucose-6-phosphatase, catalytic, 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of G6PC2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:69,041,417...69,058,337
Ensembl chr 2:69,041,417...69,058,185
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible 45 alpha |
increases expression affects expression |
ISO |
Cyclophosphamide results in increased expression of GADD45A mRNA Cyclophosphamide affects the expression of GADD45A mRNA |
CTD |
PMID:18246545 PMID:29445054 |
|
NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441
|
|
G |
Gal |
galanin and GMAP prepropeptide |
affects expression increases expression |
ISO EXP |
Cyclophosphamide affects the expression of GAL mRNA; Cyclophosphamide affects the expression of GAL protein Cyclophosphamide results in increased expression of GAL mRNA |
CTD |
PMID:16491427 PMID:17335920 PMID:18563302 |
|
NCBI chr19:3,459,915...3,464,544
Ensembl chr19:3,459,915...3,464,544
|
|
G |
Galc |
galactosylceramidase |
affects response to substance |
ISO |
GALC protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr12:98,168,543...98,226,565
Ensembl chr12:98,168,553...98,225,718
|
|
G |
Gamt |
guanidinoacetate methyltransferase |
multiple interactions |
ISO |
GAMT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:80,093,985...80,096,846
Ensembl chr10:80,093,985...80,096,846
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GAP43 protein |
CTD |
PMID:9486479 PMID:10536274 |
|
NCBI chr16:42,068,915...42,161,014
Ensembl chr16:42,068,805...42,161,014
|
|
G |
Gas2 |
growth arrest specific 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GAS2 protein |
CTD |
PMID:17475930 |
|
NCBI chr 7:51,511,560...51,644,753
Ensembl chr 7:51,511,763...51,644,723
|
|
G |
Gata3 |
GATA binding protein 3 |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of GATA3 mRNA; Cyclophosphamide results in decreased expression of GATA3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein] |
CTD |
PMID:21041162 PMID:32151603 |
|
NCBI chr 2:9,861,889...9,894,845
Ensembl chr 2:9,861,889...9,894,845
|
|
G |
Gbp2b |
guanylate binding protein 2b |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GBP1 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 3:142,300,577...142,324,940
Ensembl chr 3:142,300,608...142,324,940
|
|
G |
Gbp3 |
guanylate binding protein 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GBP3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:142,265,781...142,278,974
Ensembl chr 3:142,265,787...142,278,970
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions decreases expression |
EXP |
Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein] Cyclophosphamide results in decreased expression of GCLC mRNA; Cyclophosphamide results in decreased expression of GCLC protein |
CTD |
PMID:27633142 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gdnf |
glial cell line derived neurotrophic factor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GDNF mRNA |
CTD |
PMID:10683293 |
|
NCBI chr15:7,839,529...7,867,061
Ensembl chr15:7,840,327...7,867,056
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GEM mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:11,702,379...11,714,993
Ensembl chr 4:11,704,457...11,714,752
|
|
G |
Gfi1 |
growth factor independent 1 transcription repressor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GFI1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:107,864,521...107,873,671
Ensembl chr 5:107,864,523...107,873,902
|
|
G |
Gfra1 |
glial cell line derived neurotrophic factor family receptor alpha 1 |
multiple interactions |
ISO |
GFRA1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr19:58,224,013...58,444,387
Ensembl chr19:58,224,036...58,444,341
|
|
G |
Gimap4 |
GTPase, IMAP family member 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GIMAP4 mRNA |
CTD |
PMID:27466211 |
|
NCBI chr 6:48,661,453...48,668,996
Ensembl chr 6:48,661,483...48,668,994
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
affects expression |
ISO |
Cyclophosphamide affects the expression of GJA1 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GJB1 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr X:100,419,982...100,429,235
Ensembl chr X:100,419,984...100,429,235
|
|
G |
Glis1 |
GLIS family zinc finger 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GLIS1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:107,283,840...107,492,258
Ensembl chr 4:107,291,788...107,492,258
|
|
G |
Glod4 |
glyoxalase domain containing 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GLOD4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:76,111,221...76,134,525
Ensembl chr11:76,011,813...76,134,551
|
|
G |
Glrb |
glycine receptor, beta subunit |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GLRB mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 3:80,750,905...80,820,994
Ensembl chr 3:80,750,906...80,820,967
|
|
G |
Gls |
glutaminase |
increases expression affects response to substance |
ISO |
Cyclophosphamide results in increased expression of GLS mRNA GLS protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 PMID:21527772 |
|
NCBI chr 1:52,202,608...52,274,168
Ensembl chr 1:52,202,607...52,272,391
|
|
G |
Gm40318 |
predicted gene, 40318 |
affects response to substance decreases expression |
ISO |
S100P protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of S100P mRNA |
CTD |
PMID:16217747 PMID:17403535 |
|
NCBI chr 5:36,919,848...36,924,763
Ensembl chr 5:36,919,961...36,924,039
|
|
G |
Gm7030 |
predicted gene 7030 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of HLA-F mRNA |
CTD |
PMID:20849824 |
|
NCBI chr17:36,438,501...36,440,317
Ensembl chr17:36,420,611...36,440,317
|
|
G |
Gng12 |
guanine nucleotide binding protein (G protein), gamma 12 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GNG12 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 6:66,873,381...66,998,345
Ensembl chr 6:66,873,381...66,998,334
|
|
G |
Gpatch8 |
G patch domain containing 8 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPATCH8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:102,366,737...102,447,217
Ensembl chr11:102,366,741...102,447,218
|
|
G |
Gpr137b |
G protein-coupled receptor 137B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPR137B mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:13,528,035...13,568,250
Ensembl chr13:13,532,205...13,568,599
|
|
G |
Gpr18 |
G protein-coupled receptor 18 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of GPR18 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr14:122,148,846...122,153,300
Ensembl chr14:122,148,665...122,153,193
|
|
G |
Gpr20 |
G protein-coupled receptor 20 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPR20 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr15:73,560,346...73,579,354
Ensembl chr15:73,566,453...73,579,354
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
increases expression increases activity multiple interactions affects activity |
ISO EXP |
Cyclophosphamide results in increased expression of GPT protein Cyclophosphamide results in increased activity of GPT protein naringin affects the reaction [Cyclophosphamide affects the activity of GPT protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; Vitamin E inhibits the reaction [Cyclophosphamide results in increased expression of GPT protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein] |
CTD |
PMID:25753322 PMID:25779342 PMID:29753871 PMID:30506662 PMID:33992719 PMID:34748891 More...
|
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gpt2 |
glutamic pyruvate transaminase (alanine aminotransferase) 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of GPT2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:86,219,090...86,255,531
Ensembl chr 8:86,219,205...86,254,189
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions decreases activity |
EXP ISO |
Cyclophosphamide results in decreased expression of GPX1 mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of GPX1 mRNA] Quercetin inhibits the reaction [Cyclophosphamide results in decreased activity of GPX1 protein] |
CTD |
PMID:23542512 PMID:35906875 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GPX3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression decreases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of GPX4 protein Cyclophosphamide results in decreased expression of GPX4 protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in decreased expression of GPX4 protein] |
CTD |
PMID:17475930 PMID:37690746 |
|
NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
|
|
G |
Gsr |
glutathione reductase |
multiple interactions decreases activity |
EXP ISO |
[[Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein] which results in increased abundance of Glutathione Disulfide; [Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein] naringin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein] |
CTD |
PMID:12114195 PMID:21772021 PMID:23542512 PMID:25446862 PMID:25753322 PMID:33992719 More...
|
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gstm1 |
glutathione S-transferase, mu 1 |
multiple interactions |
ISO |
[GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide]; GSTM1 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] |
CTD |
PMID:16087946 PMID:28744217 |
|
NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289
|
|
G |
Gstm2 |
glutathione S-transferase, mu 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GSTM2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
multiple interactions increases expression affects response to substance decreases response to substance |
ISO EXP |
GSTP1 gene SNP results in increased susceptibility to [Carmustine co-treated with Doxorubicin co-treated with Cyclophosphamide co-treated with Melphalan] Cyclophosphamide results in increased expression of GSTP1 mRNA; Cyclophosphamide results in increased expression of GSTP1 protein GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] GSTP1 protein affects the susceptibility to Cyclophosphamide GSTP1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:10954901 PMID:12791655 PMID:16141653 PMID:16242832 PMID:19696094 |
|
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
|
|
G |
Gstp2 |
glutathione S-transferase, pi 2 |
multiple interactions affects response to substance |
EXP |
GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] GSTP2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:19696094 |
|
NCBI chr19:4,090,288...4,092,221
Ensembl chr19:4,090,285...4,096,023
|
|
G |
Gtf2b |
general transcription factor IIB |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GTF2B mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:142,471,008...142,489,367
Ensembl chr 3:142,470,806...142,489,367
|
|
G |
Gtf3c1 |
general transcription factor III C 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of GTF3C1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 7:125,240,126...125,306,860
Ensembl chr 7:125,240,126...125,306,952
|
|
G |
Gusb |
glucuronidase, beta |
decreases expression multiple interactions increases activity |
ISO |
Cyclophosphamide results in decreased expression of GUSB protein Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein] |
CTD |
PMID:17686619 PMID:25451569 |
|
NCBI chr 5:130,011,278...130,031,890
Ensembl chr 5:130,017,852...130,031,890
|
|
G |
Gzma |
granzyme A |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GZMA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:113,230,358...113,237,515
Ensembl chr13:113,230,359...113,237,515
|
|
G |
Gzmb |
granzyme B |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GZMB mRNA |
CTD |
PMID:15331540 |
|
NCBI chr14:56,496,293...56,499,791
Ensembl chr14:56,496,295...56,499,717
|
|
G |
H13 |
histocompatibility 13 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of H13 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:152,511,292...152,550,590
Ensembl chr 2:152,511,381...152,550,590
|
|
G |
H2-K1 |
histocompatibility 2, K1, K region |
increases expression |
EXP |
Cyclophosphamide results in increased expression of H2-K1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr17:34,214,986...34,219,316
Ensembl chr17:34,214,991...34,219,321
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased phosphorylation of H2AX protein Cyclophosphamide results in increased expression of H2AX protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in increased expression of H2AX protein] |
CTD |
PMID:32482060 PMID:33211169 PMID:34510228 PMID:37690746 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions decreases expression |
ISO |
O-1602 compound inhibits the reaction [Cyclophosphamide results in decreased expression of HBEGF protein] |
CTD |
PMID:32615180 |
|
NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858
|
|
G |
Hcrt |
hypocretin |
affects localization decreases expression |
ISO |
Cyclophosphamide affects the localization of HCRT protein Cyclophosphamide results in decreased expression of HCRT mRNA |
CTD |
PMID:17881193 PMID:19666069 |
|
NCBI chr11:100,652,519...100,653,757
Ensembl chr11:100,651,895...100,653,757
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
increases expression |
EXP |
Cyclophosphamide results in increased expression of HIF1A mRNA |
CTD |
PMID:15331540 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hinfp |
histone H4 transcription factor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of HINFP mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:44,201,509...44,217,003
Ensembl chr 9:44,203,737...44,216,968
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of HMGCS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression increases expression multiple interactions decreases expression |
ISO |
Cyclophosphamide affects the expression of HMOX1 mRNA Cyclophosphamide results in increased expression of HMOX1 mRNA; Cyclophosphamide results in increased expression of HMOX1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of HMOX1 protein; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 mRNA]; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein] Cyclophosphamide results in decreased expression of HMOX1 mRNA; Cyclophosphamide results in decreased expression of HMOX1 protein |
CTD |
PMID:11906922 PMID:17979934 PMID:18206168 PMID:18246545 PMID:19952508 PMID:20038455 PMID:20433640 PMID:32197949 PMID:32456565 PMID:37419146 More...
|
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of HMOX2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr16:4,544,225...4,584,606
Ensembl chr16:4,544,225...4,584,606
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
increases expression |
ISO |
Cyclophosphamide results in increased expression of HNRNPK protein Cyclophosphamide results in increased expression of HNRNPK mRNA |
CTD |
PMID:11599041 PMID:17475930 |
|
NCBI chr13:58,538,946...58,551,157
Ensembl chr13:58,538,956...58,551,157
|
|
G |
Hoxa1 |
homeobox A1 |
affects response to substance |
ISO |
HOXA1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:52,132,573...52,135,299
Ensembl chr 6:52,132,570...52,135,297
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis |
EXP ISO |
Cyclophosphamide results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:17116724 PMID:23677247 |
|
NCBI chr X:52,076,955...52,110,537
Ensembl chr X:52,077,014...52,110,536
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha (cytosolic), class B member 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197
|
|
G |
Hsp90b1 |
heat shock protein 90, beta (Grp94), member 1 |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of HSP90B1 mRNA Cyclophosphamide results in increased expression of HSP90B1 mRNA |
CTD |
PMID:11599041 PMID:11906922 |
|
NCBI chr10:86,526,705...86,541,308
Ensembl chr10:86,526,073...86,541,373
|
|
G |
Hspa1a |
heat shock protein 1A |
increases expression affects expression |
ISO |
Cyclophosphamide results in increased expression of HSPA1A mRNA; Cyclophosphamide results in increased expression of HSPA1A protein Cyclophosphamide affects the expression of HSPA1A mRNA |
CTD |
PMID:8917683 PMID:18246545 |
|
NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
|
|
G |
Hspa1b |
heat shock protein 1B |
decreases expression affects expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of HSPA1B mRNA Cyclophosphamide affects the expression of HSPA1B mRNA Cyclophosphamide metabolite results in increased expression of HSPA1B mRNA |
CTD |
PMID:16141653 PMID:18246545 PMID:24356939 |
|
NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214
|
|
G |
Hspa2 |
heat shock protein 2 |
affects response to substance increases expression |
ISO |
HSPA2 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of HSPA2 mRNA |
CTD |
PMID:11599041 PMID:16217747 |
|
NCBI chr12:76,450,688...76,453,712
Ensembl chr12:76,450,950...76,453,712
|
|
G |
Hspa5 |
heat shock protein 5 |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of HSPA5 mRNA Cyclophosphamide metabolite results in increased expression of HSPA5 mRNA |
CTD |
PMID:11906922 PMID:24356939 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hspa8 |
heat shock protein 8 |
affects response to substance |
ISO |
HSPA8 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
|
|
G |
Hspa9 |
heat shock protein 9 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of HSPA9 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr18:35,070,467...35,087,404
Ensembl chr18:35,070,467...35,087,410
|
|
G |
Hspb1 |
heat shock protein 1 |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of HSPB1 mRNA Cyclophosphamide results in increased expression of HSPB1 mRNA |
CTD |
PMID:11599041 PMID:11906922 PMID:18246545 |
|
NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of HSPD1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402
|
|
G |
Hspe1 |
heat shock protein 1 (chaperonin 10) |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of HSPE1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:55,127,307...55,130,476
Ensembl chr 1:55,127,291...55,130,466
|
|
G |
Hsph1 |
heat shock 105kDa/110kDa protein 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of HSPH1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841
|
|
G |
Hyls1 |
HYLS1, centriolar and ciliogenesis associated |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of HYLS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 9:35,472,117...35,481,365
Ensembl chr 9:35,472,116...35,481,694
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of HYOU1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:44,290,840...44,303,662
Ensembl chr 9:44,290,787...44,303,666
|
|
G |
Ica1 |
islet cell autoantigen 1 |
affects response to substance |
EXP |
ICA1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:11751995 |
|
NCBI chr 6:8,630,527...8,778,531
Ensembl chr 6:8,630,527...8,778,488
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
affects response to substance multiple interactions |
EXP |
ICAM1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide inhibits the reaction [Paraquat results in increased expression of ICAM1 mRNA] |
CTD |
PMID:11591119 PMID:36031164 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ID2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr12:25,143,798...25,146,091
Ensembl chr12:25,143,798...25,147,139
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of IDI1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:8,935,642...8,942,432
Ensembl chr13:8,935,537...8,942,487
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of IDO1 protein Cyclophosphamide results in increased expression of and results in increased activity of IDO1 protein; Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of IDO1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of and results in increased activity of IDO1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of IDO1 protein] |
CTD |
PMID:34748891 PMID:35906875 |
|
NCBI chr 8:25,074,148...25,086,987
Ensembl chr 8:25,074,152...25,087,025
|
|
G |
Ier3 |
immediate early response 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of IER3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815
|
|
G |
Ier5 |
immediate early response 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IER5 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:154,972,113...154,975,382
Ensembl chr 1:154,972,107...154,975,382
|
|
G |
Ifi202b |
interferon activated gene 202B |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IFI202B mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:173,790,135...173,810,410
Ensembl chr 1:173,790,134...173,810,310
|
|
G |
Ifi204 |
interferon activated gene 204 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IFI204 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:173,574,859...173,594,606
Ensembl chr 1:173,574,859...173,594,509
|
|
G |
Ifit2 |
interferon-induced protein with tetratricopeptide repeats 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IFIT2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr19:34,527,961...34,553,934
Ensembl chr19:34,528,094...34,553,819
|
|
G |
Ifna1 |
interferon alpha 1 |
multiple interactions increases expression |
ISO |
naringin inhibits the reaction [Cyclophosphamide results in increased expression of IFNA1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 4:88,768,324...88,768,893
Ensembl chr 4:88,768,324...88,768,893
|
|
G |
Ifng |
interferon gamma |
affects expression multiple interactions increases expression decreases expression decreases secretion |
EXP ISO |
Cyclophosphamide affects the expression of IFNG mRNA (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG protein]; IFNG protein inhibits the reaction [Cyclophosphamide results in increased abundance of Nitric Oxide]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein] Cyclophosphamide results in increased expression of IFNG protein Cyclophosphamide results in decreased expression of IFNG mRNA; Cyclophosphamide results in decreased expression of IFNG protein Cyclophosphamide results in increased expression of IFNG mRNA [Cyclophosphamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of IFNG protein] |
CTD |
PMID:10607705 PMID:11006010 PMID:11014644 PMID:15331540 PMID:18848347 PMID:18957084 PMID:21068404 PMID:22842586 PMID:23395935 PMID:29594315 PMID:32151603 PMID:35906875 PMID:37853057 More...
|
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of IFNGR1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:19,467,697...19,485,977
Ensembl chr10:19,467,697...19,485,977
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of IFRD1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr12:40,253,128...40,273,184
Ensembl chr12:40,251,566...40,298,503
|
|
G |
Igf2bp3 |
insulin-like growth factor 2 mRNA binding protein 3 |
affects response to substance |
ISO |
IGF2BP3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:49,062,152...49,200,225
Ensembl chr 6:49,062,157...49,191,891
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
affects response to substance decreases expression |
ISO |
IGFBP3 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:16141653 PMID:16217747 |
|
NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions |
ISO |
IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr11:98,930,820...98,943,481
Ensembl chr11:98,932,070...98,945,218
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:15331540 PMID:20849824 |
|
NCBI chr 1:72,897,224...72,914,024
Ensembl chr 1:72,897,091...72,914,043
|
|
G |
Igh-VJ558 |
immunoglobulin heavy chain (J558 family) |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of IGH-VJ558 mRNA |
CTD |
PMID:15331540 |
|
|
|
G |
Igha |
immunoglobulin heavy constant alpha |
multiple interactions decreases expression |
EXP |
ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IGHA protein] |
CTD |
PMID:37853057 |
|
NCBI chr12:113,219,824...113,223,856
Ensembl chr12:113,218,450...113,223,856
|
|
G |
Ighg1 |
immunoglobulin heavy constant gamma 1 (G1m marker) |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of IGHG1 protein ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IGHG1 protein] |
CTD |
PMID:37853057 |
|
NCBI chr12:113,290,161...113,294,143
Ensembl chr12:113,288,860...113,294,143
|
|
G |
Ighv7-1 |
immunoglobulin heavy variable 7-1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of IGH-V mRNA |
CTD |
PMID:15331540 |
|
NCBI chr12:113,860,028...113,860,566
Ensembl chr12:113,860,028...113,860,566
|
|
G |
Igkc |
immunoglobulin kappa constant |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of IGKC mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 6:70,703,419...70,703,738
Ensembl chr 6:70,703,419...70,703,950
|
|
G |
Il10 |
interleukin 10 |
decreases expression increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in decreased expression of IL10 mRNA Cyclophosphamide results in increased expression of IL10 protein Cyclophosphamide results in increased expression of IL10 mRNA Cyclophosphamide results in decreased expression of IL10 protein Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of IL10 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein] [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL10 protein |
CTD |
PMID:11014644 PMID:11948286 PMID:18848347 PMID:21068404 PMID:25451569 PMID:31651976 PMID:37263553 More...
|
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il12a |
interleukin 12a |
multiple interactions decreases expression |
EXP |
[Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IL12A protein] |
CTD |
PMID:29228376 PMID:37853057 |
|
NCBI chr 3:68,597,977...68,605,881
Ensembl chr 3:68,597,977...68,605,880
|
|
G |
Il12b |
interleukin 12b |
affects expression increases expression multiple interactions decreases expression |
EXP ISO |
Cyclophosphamide affects the expression of IL12B mRNA Cyclophosphamide results in increased expression of IL12B mRNA [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IL12B protein] Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein] |
CTD |
PMID:15331540 PMID:18957084 PMID:22842586 PMID:29228376 PMID:36416909 PMID:37853057 More...
|
|
NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860
|
|
G |
Il13ra1 |
interleukin 13 receptor, alpha 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IL13RA1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr X:35,375,761...35,434,915
Ensembl chr X:35,375,763...35,434,912
|
|
G |
Il15 |
interleukin 15 |
multiple interactions decreases secretion |
EXP |
(4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein] |
CTD |
PMID:23395935 |
|
NCBI chr 8:83,058,253...83,129,883
Ensembl chr 8:83,058,261...83,129,851
|
|
G |
Il15ra |
interleukin 15 receptor, alpha chain |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IL15RA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:11,709,992...11,739,129
Ensembl chr 2:11,710,101...11,739,128
|
|
G |
Il16 |
interleukin 16 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of IL16 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:83,292,027...83,395,479
Ensembl chr 7:83,292,033...83,394,934
|
|
G |
Il17a |
interleukin 17A |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of IL17A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein] |
CTD |
PMID:21880982 PMID:32151603 |
|
NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL18 protein |
CTD |
PMID:18848347 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression affects response to substance multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of IL1A mRNA IL1A promoter polymorphism affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of IL1A protein [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1A protein |
CTD |
PMID:15331540 PMID:16636934 PMID:18848347 PMID:31651976 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions increases response to substance decreases expression increases secretion |
EXP ISO |
Cyclophosphamide results in increased expression of IL1B mRNA; Cyclophosphamide results in increased expression of IL1B protein allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of IL1B protein]; Anthocyanins inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1B protein; [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL1B protein; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] IL1B protein results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:8634684 PMID:11948286 PMID:15331540 PMID:18206168 PMID:18483878 PMID:18710439 PMID:18848347 PMID:20126887 PMID:23695977 PMID:25451569 PMID:29228376 PMID:29753871 PMID:30506662 PMID:31651976 PMID:31779506 PMID:32151603 PMID:32456565 PMID:32615180 PMID:33992719 PMID:35762198 PMID:37263553 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1r1 |
interleukin 1 receptor, type I |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of IL1R1 mRNA naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1R1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 1:40,261,651...40,355,361
Ensembl chr 1:40,264,240...40,356,417
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IL1RN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:24,226,872...24,241,503
Ensembl chr 2:24,226,865...24,241,506
|
|
G |
Il2 |
interleukin 2 |
increases expression decreases expression multiple interactions decreases secretion |
EXP ISO |
Cyclophosphamide results in increased expression of IL2 mRNA Cyclophosphamide results in decreased expression of IL2 protein (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein] |
CTD |
PMID:11006010 PMID:11948286 PMID:18848347 PMID:23395935 PMID:32151603 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il21 |
interleukin 21 |
multiple interactions decreases expression |
EXP |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein] |
CTD |
PMID:32151603 |
|
NCBI chr 3:37,276,908...37,286,785
Ensembl chr 3:37,276,908...37,286,785
|
|
G |
Il23a |
interleukin 23, alpha subunit p19 |
decreases secretion multiple interactions decreases expression |
EXP |
Cyclophosphamide results in decreased secretion of IL23A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL23A protein] |
CTD |
PMID:23395935 PMID:32151603 |
|
NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
EXP |
[Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL3 protein |
CTD |
PMID:31651976 |
|
NCBI chr11:54,155,911...54,158,105
Ensembl chr11:54,156,129...54,158,103
|
|
G |
Il4 |
interleukin 4 |
decreases expression increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in decreased expression of IL4 mRNA; Cyclophosphamide results in decreased expression of IL4 protein Cyclophosphamide results in increased expression of IL4 mRNA; Cyclophosphamide results in increased expression of IL4 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein] |
CTD |
PMID:11006010 PMID:11014644 PMID:11948286 PMID:18848347 PMID:22842586 PMID:32151603 PMID:37853057 More...
|
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il5 |
interleukin 5 |
increases expression |
EXP ISO |
Cyclophosphamide results in increased expression of IL5 mRNA; Cyclophosphamide results in increased expression of IL5 protein |
CTD |
PMID:11006010 PMID:18848347 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression decreases secretion increases secretion |
EXP ISO |
[Cyclophosphamide co-treated with Dexamethasone] inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]; [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL6 protein; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL6 protein]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 mRNA]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 protein] allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of IL6 protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of IL6 mRNA]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein] Cyclophosphamide results in increased expression of IL6 mRNA; Cyclophosphamide results in increased expression of IL6 protein |
CTD |
PMID:10052129 PMID:11948286 PMID:17010015 PMID:18848347 PMID:20126887 PMID:21068404 PMID:22842586 PMID:23395935 PMID:23695977 PMID:25753322 PMID:29228376 PMID:30506662 PMID:31779506 PMID:32456565 PMID:32615180 PMID:34748891 PMID:35906875 PMID:36031164 PMID:37263553 More...
|
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ilf3 |
interleukin enhancer binding factor 3 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of ILF3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 9:21,278,964...21,316,659
Ensembl chr 9:21,279,167...21,316,657
|
|
G |
Irag2 |
inositol 1,4,5-triphosphate receptor associated 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of IRAG2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:145,061,357...145,120,655
Ensembl chr 6:145,061,379...145,120,660
|
|
G |
Irgm2 |
immunity-related GTPase family M member 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IRGM2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr11:58,105,803...58,113,609
Ensembl chr11:58,090,444...58,113,608
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of IRS1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ISG15 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:156,283,881...156,285,275
Ensembl chr 4:156,283,912...156,285,253
|
|
G |
Isl2 |
insulin related protein 2 (islet 2) |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ISL2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 9:55,445,961...55,454,951
Ensembl chr 9:55,445,956...55,453,464
|
|
G |
Itk |
IL2 inducible T cell kinase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ITK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:46,215,975...46,280,342
Ensembl chr11:46,215,977...46,280,342
|
|
G |
Jchain |
immunoglobulin joining chain |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of JCHAIN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 5:88,667,663...88,675,667
Ensembl chr 5:88,667,668...88,675,750
|
|
G |
Kbtbd11 |
kelch repeat and BTB (POZ) domain containing 11 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KBTBD11 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:15,059,408...15,083,333
Ensembl chr 8:15,061,025...15,083,333
|
|
G |
Kcnq4 |
potassium voltage-gated channel, subfamily Q, member 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KCNQ4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 4:120,553,331...120,605,809
Ensembl chr 4:120,553,335...120,605,809
|
|
G |
Kdm1a |
lysine (K)-specific demethylase 1A |
multiple interactions increases expression |
ISO |
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein] Cyclophosphamide results in increased expression of KDM1A protein |
CTD |
PMID:22007908 |
|
NCBI chr 4:136,277,844...136,330,127
Ensembl chr 4:136,277,851...136,330,034
|
|
G |
Kdm2a |
lysine (K)-specific demethylase 2A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of KDM2A mRNA |
CTD |
PMID:27281708 |
|
NCBI chr19:4,366,172...4,448,749
Ensembl chr19:4,364,447...4,448,313
|
|
G |
Kdm4b |
lysine (K)-specific demethylase 4B |
multiple interactions |
ISO |
KDM4B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr17:56,632,975...56,710,774
Ensembl chr17:56,633,062...56,709,870
|
|
G |
Kdr |
kinase insert domain protein receptor |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of KDR mRNA; Cyclophosphamide results in decreased expression of KDR protein Cyclophosphamide results in increased expression of KDR mRNA |
CTD |
PMID:18632792 PMID:19701751 |
|
NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of KEAP1 mRNA Quercetin inhibits the reaction [Cyclophosphamide results in decreased expression of KEAP1 mRNA] |
CTD |
PMID:37419146 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Kif21b |
kinesin family member 21B |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of KIF21B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:136,059,128...136,105,739
Ensembl chr 1:136,059,127...136,105,736
|
|
G |
Kif3a |
kinesin family member 3A |
multiple interactions |
ISO |
KIF3A mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr11:53,456,531...53,495,075
Ensembl chr11:53,458,206...53,492,794
|
|
G |
Kitl |
kit ligand |
affects expression multiple interactions increases expression |
EXP |
Cyclophosphamide affects the expression of KITL mRNA [Cyclophosphamide co-treated with Sizofiran] results in increased expression of KITL mRNA Cyclophosphamide results in increased expression of KITL mRNA |
CTD |
PMID:10052129 PMID:12624490 PMID:12662436 |
|
NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278
|
|
G |
Klf13 |
Kruppel-like transcription factor 13 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of KLF13 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:63,536,099...63,588,663
Ensembl chr 7:63,536,099...63,588,663
|
|
G |
Klf2 |
Kruppel-like transcription factor 2 (lung) |
increases expression |
EXP |
Cyclophosphamide results in increased expression of KLF2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500
|
|
G |
Klf4 |
Kruppel-like transcription factor 4 (gut) |
decreases response to substance |
ISO |
KLF4 results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:21833590 |
|
NCBI chr 4:55,527,137...55,536,984
Ensembl chr 4:55,527,143...55,532,466
|
|
G |
Klf5 |
Kruppel-like transcription factor 5 |
affects response to substance |
ISO |
KLF5 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472
|
|
G |
Klrb1c |
killer cell lectin-like receptor subfamily B member 1C |
multiple interactions |
EXP |
[Cyclophosphamide co-treated with Sizofiran] results in increased expression of KLRB1C mRNA |
CTD |
PMID:10052129 |
|
NCBI chr 6:128,755,448...128,765,514
Ensembl chr 6:128,755,448...128,766,178
|
|
G |
Krcc1 |
lysine-rich coiled-coil 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of KRCC1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:71,248,661...71,263,809
Ensembl chr 6:71,248,661...71,262,303
|
|
G |
Krt8 |
keratin 8 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of KRT8 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr15:101,905,146...101,912,777
Ensembl chr15:101,905,133...101,912,917
|
|
G |
Krt80 |
keratin 80 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of KRT80 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr15:101,246,196...101,268,043
Ensembl chr15:101,245,325...101,268,043
|
|
G |
Lama5 |
laminin, alpha 5 |
multiple interactions increases expression |
EXP |
5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of LAMA5 mRNA] |
CTD |
PMID:30760223 |
|
NCBI chr 2:179,818,166...179,867,652
Ensembl chr 2:179,818,166...179,867,652
|
|
G |
Lamc2 |
laminin, gamma 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LAMC2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:152,998,502...153,062,193
Ensembl chr 1:152,998,502...153,062,193
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LASP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:97,689,748...97,729,591
Ensembl chr11:97,689,826...97,729,590
|
|
G |
Lat |
linker for activation of T cells |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LAT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:125,962,999...125,968,877
Ensembl chr 7:125,962,996...125,968,742
|
|
G |
Lck |
lymphocyte protein tyrosine kinase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LCK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:129,442,142...129,467,415
Ensembl chr 4:129,442,137...129,467,434
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of LCN2 mRNA [Cyclophosphamide co-treated with Mecamylamine] results in increased expression of LCN2 mRNA |
CTD |
PMID:15331540 PMID:18433785 PMID:20623750 |
|
NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264
|
|
G |
Ldhb |
lactate dehydrogenase B |
affects response to substance |
ISO |
LDHB protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:142,435,975...142,453,683
Ensembl chr 6:142,435,975...142,453,683
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LEF1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:130,903,972...131,018,006
Ensembl chr 3:130,904,120...131,018,005
|
|
G |
Lgals1 |
lectin, galactose binding, soluble 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LGALS1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr15:78,810,925...78,814,665
Ensembl chr15:78,810,925...78,814,665
|
|
G |
Lgals7 |
lectin, galactose binding, soluble 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LGALS7 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:28,563,258...28,565,711
Ensembl chr 7:28,563,278...28,565,709
|
|
G |
Lhb |
luteinizing hormone beta |
decreases secretion multiple interactions increases expression |
ISO |
Cyclophosphamide results in decreased secretion of LHB protein Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of LHB protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein] |
CTD |
PMID:25446862 PMID:32197949 PMID:32456565 |
|
NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
|
|
G |
Lhx2 |
LIM homeobox protein 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LHX2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:38,229,282...38,259,747
Ensembl chr 2:38,229,293...38,259,745
|
|
G |
Limd1 |
LIM domains containing 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LIMD1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:123,306,790...123,350,617
Ensembl chr 9:123,307,771...123,350,617
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LMCD1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 6:112,250,747...112,307,384
Ensembl chr 6:112,250,719...112,307,386
|
|
G |
Lmnb1 |
lamin B1 |
multiple interactions |
ISO |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of LMNB1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of LMNB1 protein |
CTD |
PMID:15582267 |
|
NCBI chr18:56,840,885...56,886,496
Ensembl chr18:56,840,885...56,886,496
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LONRF2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:38,832,750...38,875,768
Ensembl chr 1:38,832,726...38,875,792
|
|
G |
Lsg1 |
large 60S subunit nuclear export GTPase 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LSG1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr16:30,380,187...30,406,430
Ensembl chr16:30,379,312...30,406,410
|
|
G |
Ltbr |
lymphotoxin B receptor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LTBR mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:125,283,534...125,291,026
Ensembl chr 6:125,283,534...125,290,848
|
|
G |
Ltf |
lactotransferrin |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LTF mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 9:110,848,360...110,871,834
Ensembl chr 9:110,848,339...110,871,835
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LY6A mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr15:74,866,726...74,869,880
Ensembl chr15:74,866,726...74,869,880
|
|
G |
Ly6c1 |
lymphocyte antigen 6 family member C1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LY6C1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr15:74,915,867...74,920,690
Ensembl chr15:74,915,867...74,920,679
|
|
G |
Maged1 |
MAGE family member D1 |
affects response to substance |
ISO |
MAGED1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr X:93,579,080...93,585,631
Ensembl chr X:93,579,080...93,585,749
|
|
G |
Man2b2 |
mannosidase 2, alpha B2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MAN2B2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:36,963,913...36,987,973
Ensembl chr 5:36,964,265...36,987,997
|
|
G |
Maoa |
monoamine oxidase A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MAOA mRNA |
CTD |
PMID:17403535 |
|
NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057
|
|
G |
Map3k12 |
mitogen-activated protein kinase kinase kinase 12 |
affects expression |
ISO |
Cyclophosphamide affects the expression of MAP3K12 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr15:102,406,079...102,425,311
Ensembl chr15:102,406,081...102,425,499
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
increases phosphorylation increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased phosphorylation of MAPK1 protein Cyclophosphamide results in increased expression of MAPK1 mRNA; Cyclophosphamide results in increased expression of MAPK1 protein modified form Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:11599041 PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 More...
|
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
multiple interactions affects expression decreases expression increases expression |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of MAPK14 mRNA Cyclophosphamide affects the expression of MAPK14 mRNA Cyclophosphamide results in decreased expression of MAPK14 mRNA Cyclophosphamide results in increased expression of MAPK14 protein chrysin inhibits the reaction [Cyclophosphamide results in increased expression of MAPK14 protein] |
CTD |
PMID:16322899 PMID:18246545 PMID:37263553 |
|
NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
increases expression increases phosphorylation multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of MAPK3 protein modified form Cyclophosphamide results in increased phosphorylation of MAPK3 protein Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 More...
|
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions |
ISO |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK7 protein |
CTD |
PMID:17110531 |
|
NCBI chr11:61,379,638...61,385,101
Ensembl chr11:61,379,638...61,385,232
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
EXP ISO |
Cyclophosphamide results in increased phosphorylation of MAPK8 protein GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]]; Mesna inhibits the reaction [GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein] |
CTD |
PMID:19696094 PMID:19996110 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein] |
CTD |
PMID:19996110 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
MAPT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
|
|
G |
Marchf7 |
membrane associated ring-CH-type finger 7 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MARCHF7 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:60,040,086...60,079,555
Ensembl chr 2:60,040,231...60,081,020
|
|
G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MARCKS mRNA |
CTD |
PMID:17403535 |
|
NCBI chr10:37,009,239...37,014,922
Ensembl chr10:37,009,371...37,014,916
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MCM5 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:75,836,096...75,855,067
Ensembl chr 8:75,836,197...75,855,067
|
|
G |
Mdfic |
MyoD family inhibitor domain containing |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MDFIC mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 6:15,720,660...15,802,168
Ensembl chr 6:15,720,660...15,802,168
|
|
G |
Med13l |
mediator complex subunit 13-like |
multiple interactions |
ISO |
MED13L mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 5:118,698,363...118,903,503
Ensembl chr 5:118,698,744...118,903,503
|
|
G |
Melk |
maternal embryonic leucine zipper kinase |
multiple interactions |
ISO |
MELK mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 4:44,300,876...44,364,301
Ensembl chr 4:44,300,876...44,364,675
|
|
G |
Metrn |
meteorin, glial cell differentiation regulator |
multiple interactions |
ISO |
METRN mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr17:26,013,545...26,016,019
Ensembl chr17:26,012,195...26,016,057
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MFGE8 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 7:78,783,516...78,798,808
Ensembl chr 7:78,783,516...78,798,808
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression decreases response to substance |
ISO |
Cyclophosphamide results in decreased expression of MGMT mRNA MGMT protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:15741301 PMID:17403535 |
|
NCBI chr 7:136,496,315...136,732,001
Ensembl chr 7:136,496,343...136,731,995
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MGST1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 6:138,117,525...138,133,753
Ensembl chr 6:138,117,314...138,133,753
|
|
G |
Mif |
macrophage migration inhibitory factor (glycosylation-inhibiting factor) |
multiple interactions |
ISO |
Cyclophosphamide affects the localization of and affects the expression of MIF protein; Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein] |
CTD |
PMID:19066630 |
|
NCBI chr10:75,695,187...75,696,111
Ensembl chr10:75,695,187...75,696,074
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MKI67 protein |
CTD |
PMID:33737021 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Mlh1 |
mutL homolog 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MLH1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:111,057,296...111,100,854
Ensembl chr 9:111,057,296...111,100,859
|
|
G |
Mllt11 |
myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11 |
decreases response to substance |
ISO |
MLLT11 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:31587870 |
|
NCBI chr 3:95,125,852...95,139,486
Ensembl chr 3:95,126,446...95,139,482
|
|
G |
Mmel1 |
membrane metallo-endopeptidase-like 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MMEL1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:154,954,042...154,979,987
Ensembl chr 4:154,954,042...154,979,985
|
|
G |
Mmp11 |
matrix metallopeptidase 11 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MMP11 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:75,759,056...75,768,336
Ensembl chr10:75,759,056...75,772,330
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MMP3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MMP8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:7,558,430...7,568,487
Ensembl chr 9:7,558,457...7,568,486
|
|
G |
Mpc2 |
mitochondrial pyruvate carrier 2 |
affects response to substance |
ISO |
MPC2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:165,288,829...165,308,787
Ensembl chr 1:165,288,206...165,308,783
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
affects expression |
ISO |
Cyclophosphamide affects the expression of MPG mRNA |
CTD |
PMID:11906922 |
|
NCBI chr11:32,176,505...32,182,702
Ensembl chr11:32,176,505...32,182,700
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
ISO |
Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein] |
CTD |
PMID:10749792 PMID:17979934 PMID:18710439 PMID:25451569 PMID:34748891 PMID:35906875 More...
|
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MR1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:155,003,620...155,022,560
Ensembl chr 1:155,003,023...155,022,560
|
|
G |
Ms4a3 |
membrane-spanning 4-domains, subfamily A, member 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MS4A3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr19:11,606,863...11,618,215
Ensembl chr19:11,606,860...11,618,215
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MSH2 mRNA |
CTD |
PMID:11056294 PMID:11906922 |
|
NCBI chr17:87,979,960...88,031,141
Ensembl chr17:87,979,758...88,031,141
|
|
G |
Msh3 |
mutS homolog 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MSH3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr13:92,348,387...92,491,515
Ensembl chr13:92,348,380...92,491,511
|
|
G |
Mss51 |
MSS51 mitochondrial translational activator |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MSS51 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr14:20,532,925...20,546,969
Ensembl chr14:20,532,935...20,546,969
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:83,282,686...83,302,926
Ensembl chr 6:83,282,673...83,302,890
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MTR mRNA |
CTD |
PMID:27281708 |
|
NCBI chr13:12,196,217...12,273,090
Ensembl chr13:12,197,598...12,272,999
|
|
G |
Muc13 |
mucin 13, epithelial transmembrane |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MUC13 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr16:33,614,407...33,640,299
Ensembl chr16:33,614,407...33,640,304
|
|
G |
Mup2 |
major urinary protein 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MUP2 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 4:60,135,913...60,139,977
Ensembl chr 4:60,135,932...60,154,289
|
|
G |
Mup5 |
major urinary protein 5 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MUP5 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 4:61,749,556...61,753,417
Ensembl chr 4:61,749,556...61,753,470
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
affects response to substance |
ISO |
MXI1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr19:53,298,509...53,361,724
Ensembl chr19:53,298,949...53,364,241
|
|
G |
Myh10 |
myosin, heavy polypeptide 10, non-muscle |
affects response to substance |
ISO |
MYH10 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr11:68,581,228...68,707,451
Ensembl chr11:68,582,385...68,707,458
|
|
G |
Naip2 |
NLR family, apoptosis inhibitory protein 2 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of NAIP mRNA |
CTD |
PMID:16322899 |
|
NCBI chr13:100,280,571...100,338,630
Ensembl chr13:100,280,571...100,338,600
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NAMPT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr12:32,870,334...32,903,368
Ensembl chr12:32,869,544...32,903,348
|
|
G |
Nanos1 |
nanos C2HC-type zinc finger 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of NANOS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr19:60,744,425...60,748,352
Ensembl chr19:60,744,425...60,748,352
|
|
G |
Nasp |
nuclear autoantigenic sperm protein (histone-binding) |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NASP mRNA |
CTD |
PMID:16141653 |
|
NCBI chr 4:116,458,249...116,488,894
Ensembl chr 4:116,458,249...116,485,138
|
|
G |
Ncoa7 |
nuclear receptor coactivator 7 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of NCOA7 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr10:30,521,578...30,683,401
Ensembl chr10:30,504,995...30,679,322
|
|
G |
Ndufs2 |
NADH:ubiquinone oxidoreductase core subunit S2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of NDUFS2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:171,062,426...171,078,956
Ensembl chr 1:171,062,422...171,078,957
|
|
G |
Neto2 |
neuropilin (NRP) and tolloid (TLL)-like 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NETO2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 8:86,363,347...86,428,011
Ensembl chr 8:86,363,217...86,427,553
|
|
G |
Nfatc3 |
nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of NFATC3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:106,785,450...106,857,169
Ensembl chr 8:106,785,472...106,857,169
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions decreases expression increases expression increases response to substance |
ISO EXP |
[astaxanthine co-treated with Cyclophosphamide] results in increased expression of NFE2L2 protein; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of NFE2L2 mRNA] Cyclophosphamide results in decreased expression of NFE2L2 mRNA; Cyclophosphamide results in decreased expression of NFE2L2 protein Cyclophosphamide results in increased expression of NFE2L2 mRNA; Cyclophosphamide results in increased expression of NFE2L2 protein Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] NFE2L2 gene mutant form results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:20038455 PMID:20433640 PMID:27633142 PMID:32456565 PMID:37419146 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfe2l3 |
nuclear factor, erythroid derived 2, like 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of NFE2L3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:51,409,649...51,435,752
Ensembl chr 6:51,409,650...51,435,748
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions increases phosphorylation |
EXP |
ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:30506662 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nfkbiz |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NFKBIZ mRNA |
CTD |
PMID:15331540 |
|
NCBI chr16:55,631,740...55,659,018
Ensembl chr16:55,631,738...55,659,262
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression decreases expression |
EXP ISO |
3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid methyl ester inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein]; Cyclophosphamide promotes the reaction [NGF results in increased expression of VEGFA mRNA]; VIP protein affects the reaction [Cyclophosphamide results in increased expression of NGF protein] Cyclophosphamide results in decreased expression of NGF protein Cyclophosphamide results in increased expression of NGF mRNA; Cyclophosphamide results in increased expression of NGF protein NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein] |
CTD |
PMID:10683293 PMID:16879691 PMID:18299998 PMID:18632792 PMID:19996110 PMID:20127836 PMID:32615180 More...
|
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Ngfr |
nerve growth factor receptor (TNFR superfamily, member 16) |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NGFR mRNA; Cyclophosphamide results in increased expression of NGFR protein |
CTD |
PMID:8817519 PMID:18189308 PMID:18842820 |
|
NCBI chr11:95,459,644...95,478,524
Ensembl chr11:95,459,644...95,478,561
|
|
G |
Nid1 |
nidogen 1 |
affects response to substance |
ISO |
NID1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:13,612,252...13,686,849
Ensembl chr13:13,612,136...13,686,854
|
|
G |
Nkain1 |
Na+/K+ transporting ATPase interacting 1 |
multiple interactions |
ISO |
NKAIN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 4:130,297,176...130,341,115
Ensembl chr 4:130,297,197...130,339,644
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions increases expression |
ISO |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein] |
CTD |
PMID:35762198 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NME1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr11:93,849,751...93,859,341
Ensembl chr11:93,847,805...93,859,347
|
|
G |
Nos1 |
nitric oxide synthase 1, neuronal |
decreases expression multiple interactions increases expression |
ISO |
Cyclophosphamide results in decreased expression of NOS1 protein allyl sulfide inhibits the reaction [Cyclophosphamide results in decreased expression of NOS1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of NOS1 protein] |
CTD |
PMID:31779506 PMID:35906875 |
|
NCBI chr 5:118,004,904...118,096,905
Ensembl chr 5:117,919,097...118,096,905
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases expression multiple interactions increases activity decreases expression |
EXP ISO |
Cyclophosphamide results in increased expression of NOS2 mRNA; Cyclophosphamide results in increased expression of NOS2 protein allyl sulfide inhibits the reaction [Cyclophosphamide results in decreased expression of NOS2 protein]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; ginkgolide B inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; pimagedine inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] |
CTD |
PMID:9006340 PMID:10607705 PMID:11046124 PMID:15821589 PMID:16879691 PMID:18206168 PMID:18296739 PMID:18710439 PMID:19691848 PMID:21068404 PMID:25753322 PMID:29753871 PMID:31779506 PMID:32197949 PMID:37263553 More...
|
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
decreases activity increases expression multiple interactions decreases expression |
ISO |
Cyclophosphamide results in decreased activity of NOS3 protein Cyclophosphamide results in increased expression of NOS3 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein] |
CTD |
PMID:9006340 PMID:16125470 PMID:35762198 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Nppb |
natriuretic peptide type B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NPPB protein |
CTD |
PMID:17562616 PMID:18548196 PMID:18999883 |
|
NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662
|
|
G |
Nprl2 |
NPR2 like, GATOR1 complex subunit |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NPRL2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 9:107,419,405...107,422,905
Ensembl chr 9:107,419,425...107,422,905
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
decreases expression multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of NQO1 mRNA; Cyclophosphamide results in decreased expression of NQO1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of NQO1 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] Cyclophosphamide results in increased expression of NQO1 mRNA Cyclophosphamide results in increased expression of NQO1 protein Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] |
CTD |
PMID:11906922 PMID:20038455 PMID:20433640 PMID:21041162 PMID:27633142 PMID:32197949 More...
|
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NR1H4 mRNA |
CTD |
PMID:28391356 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Cyclophosphamide results in increased activity of NR1I2 protein [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclophosphamide binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein] |
CTD |
PMID:17041008 PMID:18839173 PMID:20041327 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Nr2c2 |
nuclear receptor subfamily 2, group C, member 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NR2C2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 6:92,068,426...92,150,039
Ensembl chr 6:92,068,371...92,151,275
|
|
G |
Nrap |
nebulin-related anchoring protein |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NRAP mRNA |
CTD |
PMID:27281708 |
|
NCBI chr19:56,308,473...56,378,466
Ensembl chr19:56,308,467...56,378,469
|
|
G |
Nrdc |
nardilysin convertase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NRDC mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:108,857,852...108,918,974
Ensembl chr 4:108,857,852...108,918,974
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NRG1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825 Ensembl chr 8:32,304,579...33,374,825
|
|
G |
Nrp1 |
neuropilin 1 |
decreases expression increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of NRP1 mRNA Cyclophosphamide results in increased expression of NRP1 mRNA |
CTD |
PMID:15331540 PMID:18632792 |
|
NCBI chr 8:129,085,553...129,231,957
Ensembl chr 8:129,085,085...129,229,844
|
|
G |
Nrp2 |
neuropilin 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NRP2 mRNA |
CTD |
PMID:18632792 |
|
NCBI chr 1:62,742,476...62,857,851
Ensembl chr 1:62,742,444...62,857,854
|
|
G |
Nt5c2 |
5'-nucleotidase, cytosolic II |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NT5C2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr19:46,873,829...47,003,613
Ensembl chr19:46,871,756...47,003,592
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NTF3 mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 6:126,078,375...126,143,703
Ensembl chr 6:126,078,375...126,143,873
|
|
G |
Ntf5 |
neurotrophin 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NTF4 mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 7:45,063,119...45,066,603
Ensembl chr 7:45,063,119...45,066,603
|
|
G |
Ntrk1 |
neurotrophic tyrosine kinase, receptor, type 1 |
multiple interactions |
ISO |
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK1 protein |
CTD |
PMID:12412144 |
|
NCBI chr 3:87,685,551...87,702,549
Ensembl chr 3:87,685,551...87,702,469
|
|
G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
multiple interactions |
ISO |
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK2 protein |
CTD |
PMID:12412144 |
|
NCBI chr13:58,954,363...59,281,782
Ensembl chr13:58,954,383...59,281,784
|
|
G |
Nup42 |
nucleoporin 42 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NUP42 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:24,369,961...24,389,011
Ensembl chr 5:24,369,961...24,389,011
|
|
G |
Ocln |
occludin |
multiple interactions decreases expression increases expression |
EXP ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of OCLN protein] O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of OCLN protein] |
CTD |
PMID:32151603 PMID:32615180 |
|
NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226
|
|
G |
Odc1 |
ornithine decarboxylase, structural 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ODC1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506
|
|
G |
Ogg1 |
8-oxoguanine DNA-glycosylase 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of OGG1 protein |
CTD |
PMID:27032448 |
|
NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029
|
|
G |
Opn3 |
opsin 3 |
affects response to substance |
ISO |
OPN3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:175,489,993...175,520,198
Ensembl chr 1:175,489,987...175,520,342
|
|
G |
Osm |
oncostatin M |
affects expression |
EXP |
Cyclophosphamide affects the expression of OSM mRNA |
CTD |
PMID:12624490 |
|
NCBI chr11:4,186,831...4,191,027
Ensembl chr11:4,186,420...4,191,026
|
|
G |
P2rx3 |
purinergic receptor P2X, ligand-gated ion channel, 3 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of P2RX3 protein GR 82334 inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein]; Suramin inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein] |
CTD |
PMID:23666265 |
|
NCBI chr 2:84,826,893...84,867,446
Ensembl chr 2:84,828,927...84,867,806
|
|
G |
P2ry2 |
purinergic receptor P2Y, G-protein coupled 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of P2RY2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:100,645,775...100,661,260
Ensembl chr 7:100,645,775...100,662,073
|
|
G |
Paip1 |
polyadenylate binding protein-interacting protein 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PAIP1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr13:119,564,960...119,596,858
Ensembl chr13:119,565,137...119,594,754
|
|
G |
Pakap |
paralemmin A kinase anchor protein |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 4:57,434,475...57,896,984
Ensembl chr 4:57,717,657...57,896,984 Ensembl chr 4:57,717,657...57,896,984 Ensembl chr 4:57,717,657...57,896,984
|
|
G |
Pard3 |
par-3 family cell polarity regulator |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PARD3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 8:127,790,131...128,338,767
Ensembl chr 8:127,790,643...128,338,767
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions decreases expression increases cleavage increases expression |
ISO |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of PARP1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of PARP1 protein Cyclophosphamide results in decreased expression of PARP1 mRNA Cyclophosphamide results in increased cleavage of PARP1 protein Cyclophosphamide results in increased expression of PARP1 mRNA; Cyclophosphamide results in increased expression of PARP1 protein chrysin inhibits the reaction [Cyclophosphamide results in increased expression of PARP1 protein] |
CTD |
PMID:11599041 PMID:11723234 PMID:11906922 PMID:15582267 PMID:17898787 PMID:37263553 More...
|
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects expression increases expression decreases expression multiple interactions |
ISO EXP |
Cyclophosphamide affects the expression of PCNA mRNA Cyclophosphamide results in increased expression of PCNA mRNA Cyclophosphamide results in decreased expression of PCNA protein Cyclophosphamide results in decreased expression of PCNA mRNA coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of PCNA mRNA] |
CTD |
PMID:11056294 PMID:18246545 PMID:19701751 PMID:21041162 PMID:31557371 |
|
NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PCSK2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:143,388,053...143,658,204
Ensembl chr 2:143,388,076...143,658,205
|
|
G |
Pdcd4 |
programmed cell death 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PDCD4 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr19:53,880,662...53,926,024
Ensembl chr19:53,880,662...53,918,291
|
|
G |
Pdia3 |
protein disulfide isomerase associated 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PDIA3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:121,244,383...121,269,168
Ensembl chr 2:121,244,256...121,269,168
|
|
G |
Pdia4 |
protein disulfide isomerase associated 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PDIA4 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 6:47,773,075...47,790,446
Ensembl chr 6:47,773,075...47,790,364
|
|
G |
Peli1 |
pellino 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of PELI1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr11:21,041,283...21,100,327
Ensembl chr11:21,041,291...21,100,323
|
|
G |
Per1 |
period circadian clock 1 |
multiple interactions decreases expression |
EXP |
5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in decreased expression of PER1 mRNA] |
CTD |
PMID:30760223 |
|
NCBI chr11:68,985,934...69,000,791
Ensembl chr11:68,986,043...69,000,786
|
|
G |
Phlda2 |
pleckstrin homology like domain, family A, member 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PHLDA2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:143,055,282...143,056,882
Ensembl chr 7:143,055,282...143,056,887
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
increases mutagenesis |
ISO |
Cyclophosphamide results in increased mutagenesis of PIGA |
CTD |
PMID:22923490 |
|
NCBI chr X:163,202,814...163,216,912
Ensembl chr X:163,202,783...163,216,912
|
|
G |
Pigr |
polymeric immunoglobulin receptor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PIGR mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:130,754,421...130,779,986
Ensembl chr 1:130,754,421...130,779,986
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PLA2G4A mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PLAU mRNA |
CTD |
PMID:21527772 |
|
NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453
|
|
G |
Plod1 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of PLOD1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 4:147,994,210...148,021,233
Ensembl chr 4:147,994,210...148,021,224
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of PLOD3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:137,015,873...137,025,500
Ensembl chr 5:137,015,873...137,025,502
|
|
G |
Pms1 |
PMS1 homolog 1, mismatch repair system component |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PMS1 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 1:53,225,794...53,336,190
Ensembl chr 1:53,228,346...53,336,177
|
|
G |
Pms2 |
PMS1 homolog2, mismatch repair system component |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PMS2 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 5:143,846,379...143,922,538
Ensembl chr 5:143,846,782...143,870,786 Ensembl chr 5:143,846,782...143,870,786
|
|
G |
Polm |
polymerase (DNA directed), mu |
increases expression |
ISO |
Cyclophosphamide results in increased expression of POLM mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:5,777,860...5,788,831
Ensembl chr11:5,777,860...5,788,016
|
|
G |
Pomc |
pro-opiomelanocortin-alpha |
increases expression |
ISO |
Cyclophosphamide results in increased expression of POMC protein |
CTD |
PMID:15276878 |
|
NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity |
ISO |
Cyclophosphamide results in increased activity of PON1 protein |
CTD |
PMID:17874068 |
|
NCBI chr 6:5,168,101...5,193,824
Ensembl chr 6:5,168,090...5,193,946
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions increases expression |
ISO |
POR promotes the reaction [CYP2B6 results in increased susceptibility to Cyclophosphamide]; POR promotes the reaction [CYP2C18 results in increased susceptibility to Cyclophosphamide]; POR protein promotes the reaction [CYP2B6 protein results in increased susceptibility to Cyclophosphamide] Cyclophosphamide results in increased expression of POR mRNA |
CTD |
PMID:9766669 PMID:10919648 PMID:11599041 |
|
NCBI chr 5:135,698,894...135,764,180
Ensembl chr 5:135,698,887...135,764,180
|
|
G |
Postn |
periostin, osteoblast specific factor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of POSTN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:54,266,688...54,298,462
Ensembl chr 3:54,268,530...54,298,458
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of PPARA protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of PPARA protein] |
CTD |
PMID:29753871 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
decreases expression multiple interactions increases expression |
ISO |
Cyclophosphamide results in decreased expression of PPARG mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of PPARG mRNA] Cyclophosphamide results in increased expression of PPARG mRNA |
CTD |
PMID:25446862 PMID:27281708 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Prdm13 |
PR domain containing 13 |
affects expression |
ISO |
Cyclophosphamide affects the expression of PRDM13 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:21,675,865...21,685,963
Ensembl chr 4:21,677,480...21,685,963
|
|
G |
Prkcg |
protein kinase C, gamma |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PRKCG mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:3,352,038...3,379,615
Ensembl chr 7:3,337,704...3,379,615
|
|
G |
Prlr |
prolactin receptor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PRLR mRNA |
CTD |
PMID:15331540 |
|
NCBI chr15:10,177,324...10,349,276
Ensembl chr15:10,177,324...10,349,266
|
|
G |
Procr |
protein C receptor, endothelial |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PROCR mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:155,592,159...155,597,391
Ensembl chr 2:155,593,037...155,597,391
|
|
G |
Prtn3 |
proteinase 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PRTN3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr10:79,715,499...79,719,008
Ensembl chr10:79,710,310...79,719,008
|
|
G |
Psma5 |
proteasome subunit alpha 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PSMA5 protein |
CTD |
PMID:17475930 |
|
NCBI chr 3:108,164,242...108,187,268
Ensembl chr 3:108,164,242...108,187,290
|
|
G |
Ptcra |
pre T cell antigen receptor alpha |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PTCRA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr17:47,066,589...47,074,659
Ensembl chr17:47,066,589...47,074,638
|
|
G |
Ptger1 |
prostaglandin E receptor 1 (subtype EP1) |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PTGER1 protein |
CTD |
PMID:20346049 |
|
NCBI chr 8:84,393,171...84,399,385
Ensembl chr 8:84,393,307...84,399,382
|
|
G |
Ptger4 |
prostaglandin E receptor 4 (subtype EP4) |
multiple interactions increases expression |
ISO |
Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased expression of PTGER4 protein] |
CTD |
PMID:18514386 PMID:20346049 |
|
NCBI chr15:5,262,880...5,273,668
Ensembl chr15:5,236,142...5,273,668
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PTGES3 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr10:127,894,851...127,913,123
Ensembl chr10:127,894,823...127,913,141
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PTGS1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects response to substance multiple interactions increases expression |
ISO EXP |
PTGS2 protein affects the susceptibility to Cyclophosphamide Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; parthenolide inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 mRNA]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein] Cyclophosphamide results in increased expression of PTGS2 mRNA; Cyclophosphamide results in increased expression of PTGS2 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein] |
CTD |
PMID:12388444 PMID:15331540 PMID:16217747 PMID:17537839 PMID:18514386 PMID:19303104 PMID:25753322 PMID:29753871 PMID:37419146 More...
|
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4a1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PTP4A1 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:30,979,384...30,988,838
Ensembl chr 1:30,979,383...30,988,390 Ensembl chr 1:30,979,383...30,988,390
|
|
G |
Ptprc |
protein tyrosine phosphatase receptor type C |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PTPRC mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:137,990,601...138,103,491
Ensembl chr 1:137,990,599...138,103,446
|
|
G |
Pura |
purine rich element binding protein A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PURA mRNA |
CTD |
PMID:11599041 |
|
NCBI chr18:36,413,614...36,434,575
Ensembl chr18:36,414,150...36,425,588
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RAD50 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr11:53,540,346...53,598,146
Ensembl chr11:53,540,346...53,598,146
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of RAD51 mRNA Cyclophosphamide results in increased expression of RAD51 mRNA |
CTD |
PMID:11599041 PMID:21041162 |
|
NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926
|
|
G |
Rad54l |
RAD54 like (S. cerevisiae) |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RAD54L mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 4:115,951,458...115,980,875
Ensembl chr 4:115,951,461...115,980,887
|
|
G |
Rag1 |
recombination activating 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RAG1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:101,468,597...101,479,877
Ensembl chr 2:101,468,627...101,479,846
|
|
G |
Ramp1 |
receptor (calcitonin) activity modifying protein 1 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of RAMP1 mRNA RAMP1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 PMID:17403535 |
|
NCBI chr 1:91,107,544...91,152,918
Ensembl chr 1:91,107,544...91,152,918
|
|
G |
Rapsn |
receptor-associated protein of the synapse |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RAPSN mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:90,864,594...90,876,074
Ensembl chr 2:90,865,965...90,876,074
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RARA mRNA |
CTD |
PMID:16141653 |
|
NCBI chr11:98,818,626...98,865,768
Ensembl chr11:98,818,644...98,865,768
|
|
G |
Rarg |
retinoic acid receptor, gamma |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RARG mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:102,143,373...102,165,891
Ensembl chr15:102,143,373...102,165,952
|
|
G |
Rbpms |
RNA binding protein gene with multiple splicing |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RBPMS mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:34,272,671...34,419,925
Ensembl chr 8:34,272,671...34,419,891
|
|
G |
Rc3h1 |
RING CCCH (C3H) domains 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RC3H1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:160,733,981...160,802,546
Ensembl chr 1:160,733,988...160,802,548
|
|
G |
Rc3h2 |
ring finger and CCCH-type zinc finger domains 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RC3H2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:37,260,078...37,313,007
Ensembl chr 2:37,260,081...37,312,915
|
|
G |
Reg3b |
regenerating islet-derived 3 beta |
increases expression |
EXP ISO |
Cyclophosphamide results in increased expression of REG3A mRNA; Cyclophosphamide results in increased expression of REG3B mRNA Cyclophosphamide results in increased expression of REG3B protein |
CTD |
PMID:15331540 PMID:18295254 |
|
NCBI chr 6:78,347,868...78,350,449
Ensembl chr 6:78,347,640...78,350,449
|
|
G |
Reg3g |
regenerating islet-derived 3 gamma |
increases expression |
EXP ISO |
Cyclophosphamide results in increased expression of REG3G mRNA Cyclophosphamide results in increased expression of REG3G protein |
CTD |
PMID:15331540 PMID:18295254 |
|
NCBI chr 6:78,443,252...78,445,857
Ensembl chr 6:78,443,252...78,445,855
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
increases expression multiple interactions increases activity increases phosphorylation |
ISO EXP |
Cyclophosphamide results in increased expression of RELA mRNA; Cyclophosphamide results in increased expression of RELA protein; Cyclophosphamide results in increased expression of RELA protein modified form Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of RELA protein]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein]; parthenolide inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein modified form]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of RELA protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of RELA mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein] Cyclophosphamide results in increased localization of and results in increased activity of RELA protein; Dexamethasone inhibits the reaction [Cyclophosphamide results in increased localization of and results in increased activity of RELA protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein] |
CTD |
PMID:19303104 PMID:20433640 PMID:22099998 PMID:25451569 PMID:30506662 PMID:32197949 PMID:37419146 More...
|
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rev1 |
REV1, DNA directed polymerase |
decreases response to substance |
EXP |
REV1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:21068378 |
|
NCBI chr 1:38,091,867...38,169,191
Ensembl chr 1:38,091,867...38,168,882
|
|
G |
Ring1 |
ring finger protein 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RING1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:34,239,766...34,243,654
Ensembl chr17:34,239,766...34,243,654
|
|
G |
Ripply3 |
ripply transcriptional repressor 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RIPPLY3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr16:94,129,281...94,137,794
Ensembl chr16:94,129,279...94,137,794
|
|
G |
Rnd1 |
Rho family GTPase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RND1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr15:98,567,086...98,575,342
Ensembl chr15:98,561,302...98,575,342
|
|
G |
Rnf180 |
ring finger protein 180 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RNF180 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr13:105,267,075...105,431,406
Ensembl chr13:105,266,509...105,431,323
|
|
G |
Rnf216 |
ring finger protein 216 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RNF216 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:142,976,648...143,098,793
Ensembl chr 5:142,976,648...143,098,749
|
|
G |
Rnf44 |
ring finger protein 44 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RNF44 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr13:54,827,212...54,841,889
Ensembl chr13:54,827,212...54,841,720
|
|
G |
Rnf5 |
ring finger protein 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RNF5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:34,820,073...34,822,535
Ensembl chr17:34,820,065...34,822,664
|
|
G |
Rorc |
RAR-related orphan receptor gamma |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of RORC protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of RORC protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of RORC protein] |
CTD |
PMID:32151603 |
|
NCBI chr 3:94,280,106...94,305,583
Ensembl chr 3:94,280,101...94,305,583
|
|
G |
Rpa1 |
replication protein A1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RPA1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr11:75,191,085...75,239,478
Ensembl chr11:75,188,992...75,239,150
|
|
G |
Rpa2 |
replication protein A2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RPA2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 4:132,495,671...132,506,057
Ensembl chr 4:132,495,643...132,506,063
|
|
G |
Rps3 |
ribosomal protein S3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RPS3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 7:99,127,103...99,132,916
Ensembl chr 7:99,127,103...99,132,945
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase, polypeptide 2 |
affects response to substance |
ISO |
RPS6KA2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr17:7,356,384...7,570,714
Ensembl chr17:7,292,942...7,570,726
|
|
G |
Rraga |
Ras-related GTP binding A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RRAGA mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 4:86,493,910...86,495,522
Ensembl chr 4:86,493,905...86,495,522
|
|
G |
Rras2 |
related RAS viral (r-ras) oncogene 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RRAS2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:113,646,017...113,717,016
Ensembl chr 7:113,646,017...113,717,016
|
|
G |
Rrm1 |
ribonucleotide reductase M1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RRM1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:102,090,902...102,118,978
Ensembl chr 7:102,090,902...102,118,978
|
|
G |
Rrm2 |
ribonucleotide reductase M2 |
multiple interactions |
ISO |
RRM2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145
|
|
G |
Rrm2b |
ribonucleotide reductase M2 B (TP53 inducible) |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr15:37,924,196...37,961,562
Ensembl chr15:37,924,196...37,961,562
|
|
G |
Rtel1 |
regulator of telomere elongation helicase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RTEL1 protein |
CTD |
PMID:17475930 |
|
NCBI chr 2:180,961,504...180,998,409
Ensembl chr 2:180,961,532...180,998,409
|
|
G |
Runx3 |
runt related transcription factor 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RUNX3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 4:134,847,956...134,905,301
Ensembl chr 4:134,847,963...134,905,301
|
|
G |
Saa3 |
serum amyloid A 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SAA3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 7:46,361,422...46,365,100
Ensembl chr 7:46,361,422...46,365,124
|
|
G |
Sall1 |
spalt like transcription factor 1 |
affects response to substance |
ISO |
SALL1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 8:89,753,867...89,770,790
Ensembl chr 8:89,753,863...89,770,790
|
|
G |
Satb1 |
special AT-rich sequence binding protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SATB1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr17:52,043,215...52,140,318
Ensembl chr17:52,043,215...52,140,318
|
|
G |
Scg3 |
secretogranin III |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SCG3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 9:75,550,648...75,591,733
Ensembl chr 9:75,550,471...75,591,338
|
|
G |
Scrt1 |
scratch family zinc finger 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SCRT1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:76,400,403...76,406,329
Ensembl chr15:76,400,403...76,406,699
|
|
G |
Scube2 |
signal peptide, CUB domain, EGF-like 2 |
multiple interactions |
ISO |
SCUBE2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 7:109,397,897...109,464,886
Ensembl chr 7:109,397,883...109,464,886
|
|
G |
Sec23a |
SEC23 homolog A, COPII coat complex component |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SEC23A mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:59,005,170...59,058,803
Ensembl chr12:59,005,169...59,058,803
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SERPINE1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Sesn2 |
sestrin 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SESN2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SFN mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:133,327,867...133,329,163
Ensembl chr 4:133,327,867...133,329,479
|
|
G |
Sgce |
sarcoglycan, epsilon |
affects response to substance |
ISO |
SGCE protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:4,674,350...4,747,180
Ensembl chr 6:4,674,350...4,747,207
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SGK1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr10:21,758,083...21,875,802
Ensembl chr10:21,758,083...21,875,802
|
|
G |
Sharpin |
SHANK-associated RH domain interacting protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SHARPIN mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:76,231,240...76,235,310
Ensembl chr15:76,231,240...76,235,311
|
|
G |
Sirt5 |
sirtuin 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SIRT5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr13:43,518,849...43,549,073
Ensembl chr13:43,518,972...43,548,679
|
|
G |
Sit1 |
suppression inducing transmembrane adaptor 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SIT1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:43,482,083...43,483,709
Ensembl chr 4:43,482,081...43,483,734
|
|
G |
Slc18a3 |
solute carrier family 18 (vesicular monoamine), member 3 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of SLC18A3 protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of SLC18A3 protein] |
CTD |
PMID:32615180 |
|
NCBI chr14:32,184,394...32,186,807
Ensembl chr14:32,184,395...32,186,807
|
|
G |
Slc22a3 |
solute carrier family 22 (organic cation transporter), member 3 |
multiple interactions increases expression |
ISO |
O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of SLC22A3 protein] |
CTD |
PMID:32615180 |
|
NCBI chr17:12,638,859...12,726,591
Ensembl chr17:12,637,847...12,726,591
|
|
G |
Slc22a5 |
solute carrier family 22 (organic cation transporter), member 5 |
multiple interactions decreases expression |
ISO |
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein] Cyclophosphamide results in decreased expression of SLC22A5 mRNA; Cyclophosphamide results in decreased expression of SLC22A5 protein |
CTD |
PMID:22701146 |
|
NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Slc2a6 |
solute carrier family 2 (facilitated glucose transporter), member 6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SLC2A6 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:26,911,375...26,918,011
Ensembl chr 2:26,911,375...26,918,010
|
|
G |
Slc39a13 |
solute carrier family 39 (metal ion transporter), member 13 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SLC39A13 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:90,892,136...90,900,754
Ensembl chr 2:90,892,136...90,900,762
|
|
G |
Slc39a14 |
solute carrier family 39 (zinc transporter), member 14 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SLC39A14 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr14:70,540,916...70,588,873
Ensembl chr14:70,540,918...70,588,874
|
|
G |
Slc39a5 |
solute carrier family 39 (metal ion transporter), member 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SLC39A5 mRNA; Cyclophosphamide results in increased expression of SLC39A5 protein |
CTD |
PMID:27281708 |
|
NCBI chr10:128,231,796...128,237,145
Ensembl chr10:128,231,800...128,237,098
|
|
G |
Slc39a6 |
solute carrier family 39 (metal ion transporter), member 6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SLC39A6 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr18:24,712,938...24,736,874
Ensembl chr18:24,712,938...24,736,874
|
|
G |
Slc3a2 |
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SLC3A2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr19:8,684,931...8,700,733
Ensembl chr19:8,684,246...8,700,733
|
|
G |
Slc40a1 |
solute carrier family 40 (iron-regulated transporter), member 1 |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of SLC40A1 protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in decreased expression of SLC40A1 protein] |
CTD |
PMID:37690746 |
|
NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683
|
|
G |
Slc43a1 |
solute carrier family 43, member 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SLC43A1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:84,669,196...84,693,930
Ensembl chr 2:84,669,194...84,693,938
|
|
G |
Slc7a11 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 |
affects expression decreases expression multiple interactions |
ISO EXP |
Cyclophosphamide affects the expression of SLC7A11 mRNA Cyclophosphamide metabolite results in decreased expression of SLC7A11 mRNA Dexrazoxane inhibits the reaction [Cyclophosphamide results in decreased expression of SLC7A11 protein] |
CTD |
PMID:23824090 PMID:24356939 PMID:37690746 |
|
NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063
|
|
G |
Slfn4 |
schlafen 4 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SLFN4 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr11:83,066,001...83,081,042
Ensembl chr11:83,066,012...83,081,042
|
|
G |
Slit1 |
slit guidance ligand 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SLIT1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr19:41,586,263...41,735,714
Ensembl chr19:41,588,696...41,732,104
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SLPI mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:164,195,990...164,231,086
Ensembl chr 2:164,195,990...164,231,015
|
|
G |
Snx10 |
sorting nexin 10 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SNX10 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 6:51,500,882...51,567,659
Ensembl chr 6:51,500,881...51,567,659
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
affects response to substance |
ISO |
SOAT1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:156,255,678...156,301,898
Ensembl chr 1:156,252,095...156,301,901
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SOCS1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr16:10,601,672...10,603,400
Ensembl chr16:10,600,104...10,603,400
|
|
G |
Socs7 |
suppressor of cytokine signaling 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SOCS7 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr11:97,253,044...97,289,368
Ensembl chr11:97,253,261...97,289,368
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
decreases expression multiple interactions decreases activity |
EXP ISO |
Cyclophosphamide results in decreased expression of SOD1 mRNA [Doxorubicin co-treated with Cyclophosphamide] results in increased expression of SOD1 protein; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of SOD1 mRNA] allyl sulfide inhibits the reaction [Cyclophosphamide results in decreased activity of SOD1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in decreased activity of SOD1 protein] |
CTD |
PMID:23542512 PMID:29228376 PMID:31779506 PMID:35906875 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
increases expression decreases expression affects response to substance |
EXP ISO |
Cyclophosphamide results in increased expression of SOD2 mRNA Cyclophosphamide results in decreased expression of SOD2 mRNA SOD2 polymorphism affects the susceptibility to Cyclophosphamide |
CTD |
PMID:11599041 PMID:11906922 PMID:15331540 PMID:20309628 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sord |
sorbitol dehydrogenase |
decreases activity multiple interactions |
ISO |
Cyclophosphamide results in decreased activity of SORD protein Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of SORD protein] |
CTD |
PMID:25446862 |
|
NCBI chr 2:122,065,320...122,095,818
Ensembl chr 2:122,065,230...122,095,821
|
|
G |
Sp2 |
Sp2 transcription factor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SP2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:96,844,158...96,873,785
Ensembl chr11:96,844,167...96,873,785
|
|
G |
Sparc |
secreted acidic cysteine rich glycoprotein |
decreases expression increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of SPARC mRNA Cyclophosphamide results in increased expression of SPARC mRNA |
CTD |
PMID:15331540 PMID:17403535 |
|
NCBI chr11:55,284,985...55,310,906
Ensembl chr11:55,285,326...55,314,009
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
affects response to substance affects expression increases expression |
ISO |
SPP1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide affects the expression of SPP1 mRNA Cyclophosphamide results in increased expression of SPP1 mRNA |
CTD |
PMID:16217747 PMID:20623750 PMID:23558518 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
G |
Srek1ip1 |
splicing regulatory glutamine/lysine-rich protein 1interacting protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SREK1IP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr13:104,953,696...104,975,805
Ensembl chr13:104,928,992...104,975,782
|
|
G |
Srm |
spermidine synthase |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of SRM mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 4:148,675,970...148,679,076
Ensembl chr 4:148,675,960...148,679,450
|
|
G |
Ssrp1 |
structure specific recognition protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SSRP1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 2:84,867,519...84,877,453
Ensembl chr 2:84,867,578...84,877,453
|
|
G |
St13 |
suppression of tumorigenicity 13 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ST13 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr15:81,247,869...81,284,278
Ensembl chr15:81,247,870...81,284,278
|
|
G |
St14 |
suppression of tumorigenicity 14 (colon carcinoma) |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of ST14 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 9:30,999,886...31,043,138
Ensembl chr 9:31,000,698...31,043,149
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of STAT1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases phosphorylation decreases phosphorylation multiple interactions decreases expression |
ISO EXP |
Cyclophosphamide results in increased phosphorylation of STAT3 protein Cyclophosphamide results in decreased phosphorylation of STAT3 protein chrysin inhibits the reaction [Cyclophosphamide results in increased phosphorylation of STAT3 protein] ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of STAT3 mRNA] |
CTD |
PMID:19625377 PMID:21880982 PMID:37263553 PMID:37853057 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of STAT5B mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:100,671,557...100,741,407
Ensembl chr11:100,671,557...100,741,550
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of STIP1 mRNA |
CTD |
PMID:11906922 PMID:15331540 |
|
NCBI chr19:6,998,064...7,017,394
Ensembl chr19:6,998,070...7,017,335
|
|
G |
Stk39 |
serine/threonine kinase 39 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of STK39 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 2:68,040,789...68,302,381
Ensembl chr 2:68,040,789...68,302,612
|
|
G |
Stk4 |
serine/threonine kinase 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of STK4 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:163,916,033...163,997,444
Ensembl chr 2:163,912,242...163,997,444
|
|
G |
Stmn3 |
stathmin-like 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of STMN3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:180,948,252...180,956,293
Ensembl chr 2:180,948,252...180,956,293
|
|
G |
Stom |
stomatin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of STOM mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:35,204,002...35,227,021
Ensembl chr 2:35,203,998...35,226,988
|
|
G |
Sun1 |
Sad1 and UNC84 domain containing 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SUN1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:139,186,313...139,235,594
Ensembl chr 5:139,186,392...139,235,595
|
|
G |
Tac1 |
tachykinin 1 |
multiple interactions affects expression increases expression increases secretion |
ISO EXP |
Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased secretion of TAC1 protein] Cyclophosphamide affects the expression of TAC1 mRNA Cyclophosphamide results in increased expression of TAC1 protein |
CTD |
PMID:11312054 PMID:18184328 PMID:18563302 PMID:22842586 |
|
NCBI chr 6:7,555,061...7,562,978
Ensembl chr 6:7,554,879...7,565,834
|
|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions increases expression decreases response to substance |
EXP ISO |
[alpha-amyrin co-treated with beta-amyrin] inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] TACR1 gene mutant form results in decreased susceptibility to Cyclophosphamide GR 82334 inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein]; Suramin inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] |
CTD |
PMID:10854767 PMID:18210232 PMID:23666265 |
|
NCBI chr 6:82,378,990...82,537,085
Ensembl chr 6:82,379,315...82,537,085
|
|
G |
Tafa5 |
TAFA chemokine like family member 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of TAFA5 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr15:87,428,405...87,643,565
Ensembl chr15:87,428,500...87,643,565
|
|
G |
Tap1 |
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TAP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr17:34,406,530...34,416,199
Ensembl chr17:34,406,527...34,416,199
|
|
G |
Tat |
tyrosine aminotransferase |
affects expression decreases expression |
ISO |
Cyclophosphamide affects the expression of TAT mRNA Cyclophosphamide results in decreased expression of TAT mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 8:110,712,710...110,726,436
Ensembl chr 8:110,717,069...110,726,435
|
|
G |
Tbx21 |
T-box 21 |
multiple interactions decreases expression |
EXP |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TBX21 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TBX21 protein] |
CTD |
PMID:32151603 |
|
NCBI chr11:96,988,833...97,006,157
Ensembl chr11:96,988,897...97,006,157
|
|
G |
Tcf7 |
transcription factor 7, T cell specific |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of TCF7 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:52,137,347...52,174,211
Ensembl chr11:52,143,198...52,174,158
|
|
G |
Tcp1 |
t-complex protein 1 |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of TCP1 mRNA Cyclophosphamide results in increased expression of TCP1 mRNA |
CTD |
PMID:11599041 PMID:11906922 |
|
NCBI chr17:13,135,216...13,143,954
Ensembl chr17:13,134,588...13,143,954
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
increases activity multiple interactions |
ISO |
Cyclophosphamide results in increased activity of TDO2 protein Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of TDO2 protein] |
CTD |
PMID:35906875 |
|
NCBI chr 3:81,865,719...81,883,035
Ensembl chr 3:81,864,397...81,883,509
|
|
G |
Tex30 |
testis expressed 30 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of TEX30 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:44,125,773...44,141,650
Ensembl chr 1:44,125,773...44,141,601
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions affects expression increases secretion |
EXP ISO |
Cyclophosphamide results in increased expression of TGFB1 mRNA DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]]; TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa] Cyclophosphamide affects the expression of TGFB1 mRNA Cyclophosphamide results in increased expression of and results in increased activity of TGFB1 protein; naringin inhibits the reaction [Cyclophosphamide results in increased expression of TGFB1 mRNA] Cyclophosphamide results in increased secretion of TGFB1 protein Cyclophosphamide results in increased expression of TGFB1 mRNA; Cyclophosphamide results in increased expression of TGFB1 protein |
CTD |
PMID:9509296 PMID:12624490 PMID:19691848 PMID:21068404 PMID:23926183 PMID:33992719 More...
|
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TGFB2 mRNA |
CTD |
PMID:23558518 PMID:23926183 |
|
NCBI chr 1:186,354,984...186,441,504
Ensembl chr 1:186,354,989...186,438,186
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
multiple interactions decreases expression increases expression |
EXP ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TGFB3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TGFB3 protein] Cyclophosphamide results in increased expression of TGFB3 mRNA; Cyclophosphamide results in increased expression of TGFB3 protein |
CTD |
PMID:23926183 PMID:32151603 |
|
NCBI chr12:86,103,517...86,125,815
Ensembl chr12:86,103,519...86,125,815
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor I |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TGFBR1 mRNA; Cyclophosphamide results in increased expression of TGFBR1 protein |
CTD |
PMID:23926183 |
|
NCBI chr 4:47,353,258...47,414,926
Ensembl chr 4:47,353,222...47,414,931
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor II |
increases expression |
EXP ISO |
Cyclophosphamide results in increased expression of TGFBR2 mRNA Cyclophosphamide results in increased expression of TGFBR2 mRNA; Cyclophosphamide results in increased expression of TGFBR2 protein |
CTD |
PMID:21041162 PMID:23926183 |
|
NCBI chr 9:115,916,763...116,004,431
Ensembl chr 9:115,913,361...116,004,428
|
|
G |
Tgfbr3 |
transforming growth factor, beta receptor III |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TGFBR3 mRNA; Cyclophosphamide results in increased expression of TGFBR3 protein |
CTD |
PMID:23926183 |
|
NCBI chr 5:107,254,433...107,437,495
Ensembl chr 5:107,254,436...107,437,495
|
|
G |
Thbs1 |
thrombospondin 1 |
multiple interactions increases expression |
ISO EXP |
axitinib inhibits the reaction [Cyclophosphamide results in increased expression of THBS1 protein] Cyclophosphamide results in increased expression of THBS1 mRNA |
CTD |
PMID:15331540 PMID:18202011 |
|
NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614
|
|
G |
Thnsl2 |
threonine synthase-like 2 (bacterial) |
multiple interactions |
ISO |
THNSL2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 6:71,105,150...71,121,364
Ensembl chr 6:71,105,150...71,121,423
|
|
G |
Thy1 |
thymus cell antigen 1, theta |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of THY1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:43,954,681...43,959,876
Ensembl chr 9:43,954,681...43,959,876
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TIMP1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions decreases expression |
ISO EXP |
Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein] |
CTD |
PMID:25451569 PMID:32151603 |
|
NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529
|
|
G |
Tk1 |
thymidine kinase 1 |
increases mutagenesis |
ISO |
Cyclophosphamide metabolite results in increased mutagenesis of TK1 gene |
CTD |
PMID:32087850 |
|
NCBI chr11:117,706,345...117,716,913
Ensembl chr11:117,706,352...117,716,918
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions decreases expression |
EXP |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TLR2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TLR2 mRNA] |
CTD |
PMID:32151603 |
|
NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of TLR4 mRNA Cyclophosphamide inhibits the reaction [Paraquat results in increased expression of TLR4 mRNA]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TLR4 mRNA] |
CTD |
PMID:32151603 PMID:36031164 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tlr6 |
toll-like receptor 6 |
multiple interactions decreases expression |
EXP |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TLR6 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TLR6 mRNA] |
CTD |
PMID:32151603 |
|
NCBI chr 5:65,109,373...65,128,387
Ensembl chr 5:65,109,374...65,117,440
|
|
G |
Tlr9 |
toll-like receptor 9 |
multiple interactions increases expression |
EXP |
Cyclophosphamide inhibits the reaction [Paraquat results in increased expression of TLR9 mRNA]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of TLR9 protein] |
CTD |
PMID:29753871 PMID:36031164 |
|
NCBI chr 9:106,099,797...106,104,075
Ensembl chr 9:106,099,797...106,104,082
|
|
G |
Tm4sf1 |
transmembrane 4 superfamily member 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TM4SF1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 3:57,193,038...57,295,150
Ensembl chr 3:57,193,032...57,209,409 Ensembl chr 3:57,193,032...57,209,409
|
|
G |
Tm6sf1 |
transmembrane 6 superfamily member 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of TM6SF1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 7:81,507,810...81,533,827
Ensembl chr 7:81,508,749...81,534,182
|
|
G |
Tmed3 |
transmembrane p24 trafficking protein 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of TMED3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 9:89,581,256...89,587,096
Ensembl chr 9:89,581,259...89,587,121
|
|
G |
Tmeff1 |
transmembrane protein with EGF-like and two follistatin-like domains 1 |
affects response to substance decreases expression |
ISO |
TMEFF1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of TMEFF1 mRNA |
CTD |
PMID:16217747 PMID:27466211 |
|
NCBI chr 4:48,585,064...48,663,136
Ensembl chr 4:48,585,174...48,663,131
|
|
G |
Tmem267 |
transmembrane protein 267 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of TMEM267 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:119,624,622...120,071,995
Ensembl chr13:119,624,575...120,072,595
|
|
G |
Tmprss2 |
transmembrane protease, serine 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr16:97,365,882...97,460,741
Ensembl chr16:97,365,882...97,412,395
|
|
G |
Tnf |
tumor necrosis factor |
affects expression increases response to substance decreases response to substance multiple interactions increases expression decreases expression increases secretion |
EXP ISO |
Cyclophosphamide affects the expression of TNF mRNA TNF protein results in increased susceptibility to Cyclophosphamide TNF protein results in decreased susceptibility to Cyclophosphamide Cyclophosphamide affects the expression of TNF protein allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of TNF protein]; Anthocyanins inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of TNF mRNA]; Curcumin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of TNF mRNA]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; thymoquinone inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein] Cyclophosphamide results in increased expression of TNF mRNA; Cyclophosphamide results in increased expression of TNF protein [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of TNF protein; [Cyclophosphamide co-treated with Methylprednisolone] inhibits the reaction [Paraquat results in increased expression of TNF protein]; Cyclophosphamide inhibits the reaction [Paraquat results in increased expression of TNF mRNA]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TNF mRNA]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of TNF mRNA]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of TNF protein] Cyclophosphamide results in decreased expression of TNF mRNA; Cyclophosphamide results in decreased expression of TNF protein Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein] |
CTD |
PMID:8634684 PMID:11948286 PMID:12797522 PMID:18206168 PMID:18710439 PMID:18848347 PMID:18957084 PMID:19413659 PMID:20126887 PMID:20623750 PMID:20957680 PMID:23695977 PMID:25451569 PMID:25753322 PMID:29753871 PMID:30506662 PMID:31651976 PMID:31779506 PMID:32151603 PMID:32456565 PMID:32615180 PMID:33737140 PMID:35762198 PMID:36031164 PMID:36416909 PMID:37263553 PMID:37419146 PMID:37853057 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip3 |
tumor necrosis factor, alpha-induced protein 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TNFAIP3 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405
|
|
G |
Tnfrsf14 |
tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TNFRSF14 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:155,002,944...155,013,077
Ensembl chr 4:155,006,390...155,013,020
|
|
G |
Tnfrsf18 |
tumor necrosis factor receptor superfamily, member 18 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of TNFRSF18 mRNA |
CTD |
PMID:15591121 |
|
NCBI chr 4:156,110,779...156,113,351
Ensembl chr 4:156,110,621...156,113,352
|
|
G |
Tnfrsf19 |
tumor necrosis factor receptor superfamily, member 19 |
multiple interactions increases expression |
EXP |
5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of TNFRSF19 mRNA] |
CTD |
PMID:30760223 |
|
NCBI chr14:61,201,283...61,284,304
Ensembl chr14:61,201,324...61,283,939
|
|
G |
Tnfsf9 |
tumor necrosis factor (ligand) superfamily, member 9 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TNFSF9 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr17:57,412,113...57,414,757
Ensembl chr17:57,412,325...57,414,757
|
|
G |
Tnni3 |
troponin I, cardiac 3 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of TNNI3 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein] |
CTD |
PMID:17562616 PMID:18548196 PMID:35762198 |
|
NCBI chr 7:4,521,304...4,526,228
Ensembl chr 7:4,521,304...4,527,228
|
|
G |
Top2a |
topoisomerase (DNA) II alpha |
multiple interactions increases expression |
ISO |
TOP2A protein affects the susceptibility to [Cyclophosphamide co-treated with Epirubicin co-treated with Fluorouracil]; TOP2A protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] Cyclophosphamide results in increased expression of TOP2A mRNA |
CTD |
PMID:11599041 PMID:16682728 PMID:18465341 |
|
NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015
|
|
G |
Tpd52 |
tumor protein D52 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of TPD52 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 3:8,991,590...9,069,824
Ensembl chr 3:8,990,653...9,069,783
|
|
G |
Tpm1 |
tropomyosin 1, alpha |
affects response to substance |
ISO |
TPM1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 9:66,929,872...66,956,954
Ensembl chr 9:66,929,872...66,956,688
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of TRIB3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952
|
|
G |
Trim32 |
tripartite motif-containing 32 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TRIM32 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:65,523,223...65,534,477
Ensembl chr 4:65,523,223...65,534,475
|
|
G |
Trim58 |
tripartite motif-containing 58 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TRIM58 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:58,531,232...58,543,277
Ensembl chr11:58,531,291...58,543,230
|
|
G |
Triml1 |
tripartite motif family-like 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of TRIML1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:43,582,843...43,633,531
Ensembl chr 8:43,582,844...43,594,523
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions affects response to substance increases mutagenesis increases expression increases activity |
ISO EXP |
astaxanthine inhibits the reaction [Cyclophosphamide results in increased expression of TP53 protein]; chlorophyllin inhibits the reaction [Cyclophosphamide results in increased mutagenesis of TP53 exon]; Curcumin inhibits the reaction [Cyclophosphamide results in increased mutagenesis of TP53 exon]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of TP53 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of TP53 mRNA] TP53 protein affects the susceptibility to Cyclophosphamide TRP53 affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of TP53 mRNA; Cyclophosphamide results in increased expression of TP53 protein TP53 protein promotes the reaction [Methotrexate results in increased susceptibility to Cyclophosphamide metabolite] Cyclophosphamide metabolite results in increased activity of TP53 protein |
CTD |
PMID:9610789 PMID:10766175 PMID:15182437 PMID:19227835 PMID:20038455 PMID:20655369 PMID:22010212 PMID:32197949 More...
|
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
multiple interactions |
ISO |
[2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide binds to and results in decreased activity of TRPA1 protein] which results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:23523557 |
|
NCBI chr 1:14,942,868...14,989,086
Ensembl chr 1:14,942,872...14,989,086
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of TRPV1 mRNA alternative form |
CTD |
PMID:18797299 |
|
NCBI chr11:73,124,975...73,152,148
Ensembl chr11:73,125,118...73,152,068
|
|
G |
Try4 |
trypsin 4 |
affects response to substance |
ISO |
PRSS3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:41,279,206...41,282,467
Ensembl chr 6:41,279,203...41,282,466
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TUBA4A mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:75,190,867...75,197,905
Ensembl chr 1:75,190,872...75,196,509
|
|
G |
Tubb2b |
tubulin, beta 2B class IIB |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of TUBB2B mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:34,310,991...34,314,337
Ensembl chr13:34,310,731...34,314,449
|
|
G |
Tug1 |
taurine upregulated gene 1 |
multiple interactions decreases expression |
ISO |
sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of TUG1 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of TUG1 mRNA] |
CTD |
PMID:32197949 |
|
NCBI chr11:3,589,313...3,599,021
Ensembl chr11:3,589,785...3,599,673
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions decreases expression |
EXP |
ganoderic acid A inhibits the reaction [Cyclophosphamide results in decreased expression of TXN protein] |
CTD |
PMID:30506662 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions increases expression |
EXP |
ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of TXNIP protein] |
CTD |
PMID:30506662 |
|
NCBI chr 3:96,465,273...96,469,173
Ensembl chr 3:96,465,273...96,469,199
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases activity |
EXP |
Cyclophosphamide results in decreased activity of TXNRD1 protein |
CTD |
PMID:19168513 |
|
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
|
|
G |
Tymp |
thymidine phosphorylase |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of TYMP protein; [Epirubicin co-treated with Cyclophosphamide] results in increased expression of TYMP protein |
CTD |
PMID:15150550 |
|
NCBI chr15:89,255,834...89,261,282
Ensembl chr15:89,256,134...89,261,242
|
|
G |
Tyrobp |
TYRO protein tyrosine kinase binding protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of TYROBP mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:30,113,207...30,117,007
Ensembl chr 7:30,113,185...30,117,010
|
|
G |
Ubd |
ubiquitin D |
increases expression |
EXP |
Cyclophosphamide results in increased expression of UBD mRNA |
CTD |
PMID:15331540 |
|
NCBI chr17:37,504,783...37,506,992
Ensembl chr17:37,504,783...37,506,986
|
|
G |
Ubr7 |
ubiquitin protein ligase E3 component n-recognin 7 (putative) |
increases expression |
ISO |
Cyclophosphamide results in increased expression of UBR7 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:102,724,234...102,743,960
Ensembl chr12:102,724,226...102,743,966
|
|
G |
Ucp1 |
uncoupling protein 1 (mitochondrial, proton carrier) |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of UCP1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:84,016,977...84,025,085
Ensembl chr 8:84,016,981...84,025,081
|
|
G |
Umod |
uromodulin |
multiple interactions decreases expression |
ISO |
O-1602 compound inhibits the reaction [Cyclophosphamide results in decreased expression of UMOD protein] |
CTD |
PMID:32615180 |
|
NCBI chr 7:119,061,931...119,078,485
Ensembl chr 7:119,061,934...119,078,505
|
|
G |
Ung |
uracil DNA glycosylase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of UNG mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 5:114,268,427...114,277,382
Ensembl chr 5:114,268,447...114,277,384
|
|
G |
Upk1a |
uroplakin 1A |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of UPK1A mRNA Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK1A mRNA] |
CTD |
PMID:19654953 PMID:20186394 |
|
NCBI chr 7:30,302,517...30,312,159
Ensembl chr 7:30,302,517...30,312,272
|
|
G |
Upk1b |
uroplakin 1B |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of UPK1B mRNA Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK1B mRNA] |
CTD |
PMID:19654953 PMID:20186394 |
|
NCBI chr16:38,593,544...38,620,565
Ensembl chr16:38,593,546...38,620,690
|
|
G |
Upk2 |
uroplakin 2 |
decreases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in decreased expression of UPK2 mRNA; Cyclophosphamide results in decreased expression of UPK2 protein Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 mRNA]; Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 protein] Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 mRNA]; Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 protein]; S-allylcysteine inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 mRNA]; S-allylcysteine inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 protein] |
CTD |
PMID:19654953 PMID:20186394 PMID:27234646 |
|
NCBI chr 9:44,364,012...44,366,064
Ensembl chr 9:44,364,012...44,366,273
|
|
G |
Upk3a |
uroplakin 3A |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of UPK3A mRNA; Cyclophosphamide results in decreased expression of UPK3A protein Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK3A mRNA]; Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK3A protein] |
CTD |
PMID:19654953 PMID:20186394 |
|
NCBI chr15:84,901,342...84,906,761
Ensembl chr15:84,901,342...84,906,748
|
|
G |
Usp36 |
ubiquitin specific peptidase 36 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of USP36 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:118,150,477...118,181,086
Ensembl chr11:118,150,477...118,181,070
|
|
G |
Usp44 |
ubiquitin specific peptidase 44 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of USP44 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:93,655,831...93,696,792
Ensembl chr10:93,667,417...93,693,950
|
|
G |
Usp5 |
ubiquitin specific peptidase 5 (isopeptidase T) |
multiple interactions increases expression |
EXP |
3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of USP5 protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of USP5 protein Cyclophosphamide results in increased expression of USP5 protein |
CTD |
PMID:29129814 |
|
NCBI chr 6:124,791,982...124,806,404
Ensembl chr 6:124,791,982...124,806,447
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of VCAM1 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
G |
Vdr |
vitamin D (1,25-dihydroxyvitamin D3) receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of VDR mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:97,752,308...97,806,177
Ensembl chr15:97,752,306...97,808,511
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression affects expression decreases expression |
EXP ISO |
Cyclophosphamide promotes the reaction [NGF results in increased expression of VEGFA mRNA] Cyclophosphamide results in increased expression of VEGFA mRNA Cyclophosphamide affects the expression of VEGFA protein Cyclophosphamide metabolite results in decreased expression of VEGFA mRNA |
CTD |
PMID:18632792 PMID:24356939 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vim |
vimentin |
affects expression |
ISO |
Cyclophosphamide affects the expression of VIM mRNA |
CTD |
PMID:10859244 |
|
NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637
|
|
G |
Vip |
vasoactive intestinal polypeptide |
multiple interactions affects expression affects response to substance |
EXP ISO |
VIP protein affects the reaction [Cyclophosphamide results in increased expression of NGF protein]; VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of CXCL1 protein]; VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] Cyclophosphamide affects the expression of VIP mRNA VIP affects the susceptibility to Cyclophosphamide |
CTD |
PMID:18299998 PMID:18483878 PMID:18563302 |
|
NCBI chr10:5,589,131...5,597,617
Ensembl chr10:5,589,218...5,597,617
|
|
G |
Vipr1 |
vasoactive intestinal peptide receptor 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of VIPR1 mRNA |
CTD |
PMID:18563302 |
|
NCBI chr 9:121,471,782...121,502,020
Ensembl chr 9:121,471,782...121,502,020
|
|
G |
Vipr2 |
vasoactive intestinal peptide receptor 2 |
affects expression |
ISO |
Cyclophosphamide affects the expression of VIPR2 mRNA |
CTD |
PMID:18563302 |
|
NCBI chr12:116,041,040...116,117,842
Ensembl chr12:116,041,346...116,109,881
|
|
G |
Vldlr |
very low density lipoprotein receptor |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of VLDLR mRNA |
CTD |
PMID:24356939 |
|
NCBI chr19:27,190,070...27,231,631
Ensembl chr19:27,193,884...27,231,631
|
|
G |
Was |
Wiskott-Aldrich syndrome |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of WAS mRNA |
CTD |
PMID:21041162 |
|
NCBI chr X:7,947,705...7,956,730
Ensembl chr X:7,947,692...7,956,737
|
|
G |
Xaf1 |
XIAP associated factor 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of XAF1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr11:72,192,229...72,204,560
Ensembl chr11:72,192,455...72,204,559
|
|
G |
Xdh |
xanthine dehydrogenase |
increases activity multiple interactions |
ISO |
Cyclophosphamide results in increased activity of XDH protein Rutin inhibits the reaction [Cyclophosphamide results in increased activity of XDH protein] |
CTD |
PMID:25753322 |
|
NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191
|
|
G |
Xist |
inactive X specific transcripts |
increases expression |
EXP |
Cyclophosphamide results in increased expression of XIST mRNA |
CTD |
PMID:15331540 |
|
NCBI chr X:102,503,979...102,526,839
Ensembl chr X:102,503,972...102,526,860
|
|
G |
Xpc |
xeroderma pigmentosum, complementation group C |
affects expression increases expression |
ISO |
Cyclophosphamide affects the expression of XPC mRNA Cyclophosphamide results in increased expression of XPC mRNA |
CTD |
PMID:11056294 PMID:29445054 |
|
NCBI chr 6:91,466,287...91,492,870
Ensembl chr 6:91,466,287...91,492,870
|
|
G |
Xrcc1 |
X-ray repair complementing defective repair in Chinese hamster cells 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of XRCC1 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 7:24,246,124...24,272,863
Ensembl chr 7:24,245,714...24,272,865
|
|
G |
Xrcc6 |
X-ray repair complementing defective repair in Chinese hamster cells 6 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of XRCC6 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr15:81,868,805...81,924,286
Ensembl chr15:81,872,036...81,924,286
|
|
G |
Zap70 |
zeta-chain (TCR) associated protein kinase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ZAP70 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:36,800,912...36,821,899
Ensembl chr 1:36,800,879...36,821,899
|
|
G |
Zbtb33 |
zinc finger and BTB domain containing 33 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZBTB33 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr X:37,278,670...37,285,923
Ensembl chr X:37,278,670...37,285,923
|
|
G |
Zbtb41 |
zinc finger and BTB domain containing 41 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZBTB41 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:139,349,916...139,380,743
Ensembl chr 1:139,350,026...139,380,743
|
|
G |
Zc3h12b |
zinc finger CCCH-type containing 12B |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZC3H12B mRNA |
CTD |
PMID:27281708 |
|
NCBI chr X:94,755,206...94,976,262
Ensembl chr X:94,755,284...94,976,243
|
|
G |
Zdhhc1 |
zinc finger, DHHC domain containing 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZDHHC1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:106,199,055...106,223,694
Ensembl chr 8:106,199,055...106,223,534
|
|
G |
Zfp142 |
zinc finger protein 142 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZFP142 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:74,605,490...74,627,308
Ensembl chr 1:74,604,286...74,627,405
|
|
G |
Zfp169 |
zinc finger protein 169 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZFP169 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr13:48,634,239...48,666,969
Ensembl chr13:48,641,123...48,666,927
|
|
G |
Zfp219 |
zinc finger protein 219 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP219 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr14:52,243,532...52,258,597
Ensembl chr14:52,243,534...52,258,190
|
|
G |
Zfp24 |
zinc finger protein 24 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP24 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr18:24,142,774...24,155,294
Ensembl chr18:24,142,759...24,153,867
|
|
G |
Zfp263 |
zinc finger protein 263 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP263 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr16:3,561,883...3,568,654
Ensembl chr16:3,561,957...3,568,654
|
|
G |
Zfp280d |
zinc finger protein 280D |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP280D mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:72,181,900...72,271,061
Ensembl chr 9:72,182,142...72,271,059
|
|
G |
Zfp318 |
zinc finger protein 318 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZFP318 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:46,694,444...46,731,846
Ensembl chr17:46,694,657...46,731,846
|
|
G |
Zfp36l1 |
zinc finger protein 36, C3H type-like 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZFP36L1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:80,154,534...80,159,787
Ensembl chr12:80,154,528...80,159,787
|
|
G |
Zfp385a |
zinc finger protein 385A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZFP385A mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:103,222,322...103,248,537
Ensembl chr15:103,222,322...103,248,520
|
|
G |
Zfp385c |
zinc finger protein 385C |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP385C mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:100,517,045...100,583,292
Ensembl chr11:100,518,369...100,583,281
|
|
G |
Zfp414 |
zinc finger protein 414 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP414 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:33,848,066...33,850,690
Ensembl chr17:33,848,064...33,850,753
|
|
G |
Zfp459 |
zinc finger protein 459 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ZFP459 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr13:67,553,831...67,569,537
Ensembl chr13:67,553,828...67,569,537
|
|
G |
Zfp513 |
zinc finger protein 513 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP513 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:31,356,325...31,360,007
Ensembl chr 5:31,356,325...31,359,647
|
|
G |
Zfp532 |
zinc finger protein 532 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZFP532 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr18:65,713,301...65,822,514
Ensembl chr18:65,712,983...65,822,514
|
|
G |
Zfp622 |
zinc finger protein 622 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP622 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:25,984,452...25,998,568
Ensembl chr15:25,984,452...25,998,567
|
|
G |
Zfp652 |
zinc finger protein 652 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP652 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:95,639,893...95,655,541
Ensembl chr11:95,603,499...95,725,941
|
|
G |
Zfp655 |
zinc finger protein 655 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZFP655 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:145,168,503...145,184,116
Ensembl chr 5:145,168,525...145,184,112
|
|
G |
Zfp827 |
zinc finger protein 827 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZFP827 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:79,753,754...79,920,397
Ensembl chr 8:79,755,066...79,920,395
|
|
G |
Zfr |
zinc finger RNA binding protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZFR mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:12,117,649...12,185,535
Ensembl chr15:12,117,917...12,185,769
|
|
G |
Zhx3 |
zinc fingers and homeoboxes 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ZHX3 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:160,612,367...160,714,910
Ensembl chr 2:160,590,628...160,714,918
|
|
G |
Zic1 |
zinc finger protein of the cerebellum 1 |
affects response to substance |
ISO |
ZIC1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 9:91,240,111...91,250,136
Ensembl chr 9:91,240,111...91,247,863
|
|
G |
Zzef1 |
zinc finger, ZZ-type with EF hand domain 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ZZEF1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:72,686,976...72,817,946
Ensembl chr11:72,687,052...72,817,946
|
|